<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001477.pub3" GROUP_ID="ARI" ID="309299081614131806" MERGED_FROM="" MODIFIED="2013-08-13 23:40:52 +0100" MODIFIED_BY="Liz Dooley" REVIEW_NO="A015" REVMAN_SUB_VERSION="5.2.6 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="12.0">
<COVER_SHEET MODIFIED="2013-08-13 23:40:52 +0100" MODIFIED_BY="Liz Dooley">
<TITLE MODIFIED="2008-02-18 13:41:59 +1000" MODIFIED_BY="[Empty name]">Antibiotics for preventing complications in children with measles</TITLE>
<CONTACT MODIFIED="2013-08-13 23:40:52 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="18169" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Sushil</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Kabra</LAST_NAME><POSITION>Additional Professor</POSITION><EMAIL_1>skkabra@hotmail.com</EMAIL_1><EMAIL_2>skkabra@rediffmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Pediatric Pulmonology Division, Department of Pediatrics</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><CITY>Ansari Nagar</CITY><ZIP>110029</ZIP><REGION>New Delhi</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 11 2659 4610</PHONE_1><PHONE_2>+91 11 2658 8941</PHONE_2><FAX_1>+91 11 2658 8663</FAX_1><FAX_2>+91 11 2658 8641</FAX_2></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2013-08-13 23:40:52 +0100" MODIFIED_BY="Liz Dooley"><PERSON ID="18169" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Sushil</FIRST_NAME><MIDDLE_INITIALS>K</MIDDLE_INITIALS><LAST_NAME>Kabra</LAST_NAME><POSITION>Additional Professor</POSITION><EMAIL_1>skkabra@hotmail.com</EMAIL_1><EMAIL_2>skkabra@rediffmail.com</EMAIL_2><ADDRESS><DEPARTMENT>Pediatric Pulmonology Division, Department of Pediatrics</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><CITY>Ansari Nagar</CITY><ZIP>110029</ZIP><REGION>New Delhi</REGION><COUNTRY CODE="IN">India</COUNTRY><PHONE_1>+91 11 2659 4610</PHONE_1><PHONE_2>+91 11 2658 8941</PHONE_2><FAX_1>+91 11 2658 8663</FAX_1><FAX_2>+91 11 2658 8641</FAX_2></ADDRESS></PERSON><PERSON ID="CF7B01F482E26AA2004D2786DBEA97F7" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Rakesh</FIRST_NAME><LAST_NAME>Lodha</LAST_NAME><POSITION>Assistant Professor</POSITION><EMAIL_1>rakesh_lodha@hotmail.com</EMAIL_1><ADDRESS><DEPARTMENT>Department of Pediatrics</DEPARTMENT><ORGANISATION>All India Institute of Medical Sciences</ORGANISATION><CITY>Ansari Nagar</CITY><ZIP>110029</ZIP><REGION>New Delhi</REGION><COUNTRY CODE="IN">India</COUNTRY><FAX_1>+91 11 2658 8663</FAX_1><FAX_2>+91 11 26588641</FAX_2></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2013-06-28 13:17:58 +1000" MODIFIED_BY="[Empty name]">
<UP_TO_DATE>
<DATE DAY="24" MONTH="5" YEAR="2013"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="24" MONTH="5" YEAR="2013"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="24" MONTH="5" YEAR="2015"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2010"/>
<LAST_CITATION_ISSUE ISSUE="3" YEAR="2008"/>
</DATES>
<WHATS_NEW MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2013-08-09 19:59:12 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Additional information on measles outbreaks included in the update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="24" MONTH="5" YEAR="2013"/>
<DESCRIPTION>
<P>Searches updated; no new trials were included in the update.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2013-06-28 13:18:05 +1000" MODIFIED_BY="[Empty name]">
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2013-06-28 13:18:05 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="7" MONTH="4" YEAR="2011"/>
<DESCRIPTION>
<P>Searches conducted. No new trials were identified in this updated review.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2011-01-11 08:34:49 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="5" MONTH="8" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-08-05 12:00:27 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="21" MONTH="1" YEAR="2010"/>
<DESCRIPTION>
<P>Contact details updated.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-01-21 10:17:39 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="16" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-01-21 10:17:39 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Change in authors.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-01-21 10:17:39 +1000" MODIFIED_BY="Liz Dooley">
<DATE DAY="4" MONTH="1" YEAR="2008"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-03 12:03:16 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="27" MONTH="2" YEAR="2001"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-03 11:57:52 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="17" MONTH="8" YEAR="1999"/>
<DESCRIPTION>
<P>Searches conducted. Feedback added.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2008-03-03 11:43:32 +1000" MODIFIED_BY="[Empty name]">
<DATE DAY="9" MONTH="12" YEAR="1998"/>
<DESCRIPTION>
<P>Searches conducted.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>All India Institute of Medical Sciences, New Delhi</NAME>
<COUNTRY CODE="IN">India</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-02-19 15:03:22 +1000" MODIFIED_BY="[Empty name]">Antibiotics for preventing complications in children with measles</TITLE>
<SUMMARY_BODY MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>Measles is an infectious disease caused by a virus. There is an effective vaccine which can prevent measles, nevertheless 30 to 40 million people worldwide still develop measles annually. Each year measles causes more than half a million deaths and is responsible for an estimated 44% of the 1.7 million vaccine-preventable deaths among children. Measles is associated with complications such as pneumonia, ear infections, throat infections, diarrhea and conjunctivitis.</P>
<P>Currently, the administration of two doses of vitamin A is recommended for the prevention of these complications in children below two years of age. Another method to prevent post-measles complications is to give antibiotics to children. The objective of this review was to assess the effects of antibiotics given to children with measles to reduce pneumonia, other morbidities and mortality. This review contains search results from May 2013 and included seven controlled clinical trials (1263 children), showed that children with measles who were given antibiotics had a lower incidence of pneumonia, ear infections and tonsillitis. However, there were no benefits for conjunctivitis or gastroenteritis. No major side effects attributable to administration of the study drugs were observed. As many of the studies were performed five decades ago with weak methodology using old antibiotics, there is a need for randomized controlled trials using newer antibiotics.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<ABS_BACKGROUND MODIFIED="2011-04-12 11:10:21 +1000" MODIFIED_BY="[Empty name]">
<P>Measles is the leading killer among vaccine-preventable diseases; it is responsible for an estimated 44% of the 1.7 million vaccine-preventable deaths among children annually.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2008-03-13 10:54:28 +1000" MODIFIED_BY="Liz Dooley">
<P>To assess the effects of antibiotics given to children with measles to prevent complications and reduce pneumonia, other morbidities and mortality.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2013-08-09 19:59:49 +1000" MODIFIED_BY="[Empty name]">
<P>We searched CENTRAL 2013, Issue 4, MEDLINE (1966 to May week 4, 2013) and EMBASE (1980 to May 2013).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2011-04-12 11:14:58 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and quasi-RCTs comparing antibiotics with placebo or no treatment, to prevent complications in children with measles.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors independently extracted data and assessed trial quality.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>Seven trials with 1263 children were included. The methodological quality of most studies was poor. Only two studies were randomized, double-blind trials. There was variation in antibiotics used, their doses, schedule and evaluation of outcome. Pooled study data showed that the incidence of pneumonia was lower in the treatment group compared to the control group. However, the difference was not statistically significant. Of the 654 children who received antibiotics, 27 (4.1%) developed pneumonia; while out of 609 children in the control group, 59 (9.6%) developed pneumonia (odds ratio (OR) 0.35; 95% confidence interval (0.12 to 1.01). The one trial that showed an increase in the rate of pneumonia with antibiotics was conducted in 1942 and compared oral sulfathiazole with symptomatic treatment. If the results of this trial are removed from the meta-analysis, there is a statistically significant reduction in the incidence of pneumonia in children receiving antibiotics (OR 0.26; 95% CI 0.12 to 0.60). The incidence of other complications was significantly lower in children receiving antibiotics: purulent otitis media (OR 0.34; 95% CI 0.16 to 0.73) and tonsillitis (OR 0.08; 95% CI 0.01 to 0.72). There was no difference in the incidence of conjunctivitis (OR 0.39; 95% CI 0.15 to 1.0), diarrhea (OR 0.53; 95% CI 0.23 to 1.22) or croup (OR 0.16; 95% CI 0.01 to 4.06). No major adverse effects attributable to antibiotics were reported.<BR/>
</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2013-06-20 00:47:05 +1000" MODIFIED_BY="[Empty name]">
<P>The studies reviewed were of poor quality and used older antibiotics. This review suggests a beneficial effect of antibiotics in preventing complications such as pneumonia, purulent otitis media and tonsillitis in children with measles. On the basis of this review, it is not possible to recommend definitive guidelines on the type of antibiotic, duration or the day of initiation. There is a need for more evidence from high-quality RCTs to answer these questions.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>Measles is an acute viral infection that is spread by respiratory secretions and is highly contagious. It is responsible for very high morbidity and mortality due to serious complications such as diarrhea, otitis media, pneumonia or encephalitis. It was the leading killer among vaccine-preventable diseases, causing an estimated 44% of the 1.7 million vaccine-preventable deaths among children each year (<LINK REF="REF-Anonymous-2002" TYPE="REFERENCE">Anonymous 2002</LINK>). Although it is well-controlled in industrialised countries, intermittent outbreaks occur wherever vaccination coverage is low (<LINK REF="REF-Curtale-2010" TYPE="REFERENCE">Curtale 2010</LINK>; <LINK REF="REF-Muscat-2009" TYPE="REFERENCE">Muscat 2009</LINK>; <LINK REF="REF-Nmor-2011" TYPE="REFERENCE">Nmor 2011</LINK>). The death rate from measles has declined sharply in the past decades, largely as a result of intensive vaccination efforts (<LINK REF="REF-Wolfson-2009" TYPE="REFERENCE">Wolfson 2009</LINK>). Despite this, periodic outbreaks continue to occur and may result in morbidity and mortality (<LINK REF="REF-Mishra-2009" TYPE="REFERENCE">Mishra 2009</LINK>). Over past few years major outbreaks of measles have been reported from different parts of world (<LINK REF="REF-Anonymous-2013" TYPE="REFERENCE">Anonymous 2013</LINK>; <LINK REF="REF-Antona-2013" TYPE="REFERENCE">Antona 2013</LINK>; <LINK REF="REF-Bandyopadhyay-2013" TYPE="REFERENCE">Bandyopadhyay 2013</LINK>; <LINK REF="REF-Corbin-2013" TYPE="REFERENCE">Corbin 2013</LINK>; <LINK REF="REF-Delaporte-2013" TYPE="REFERENCE">Delaporte 2013</LINK>; <LINK REF="REF-De-Serres-2013" TYPE="REFERENCE">De Serres 2013</LINK>; <LINK REF="REF-Ghebrehewet-2013" TYPE="REFERENCE">Ghebrehewet 2013</LINK>; <LINK REF="REF-Grout-2013" TYPE="REFERENCE">Grout 2013</LINK>; <LINK REF="REF-le-Roux-2012" TYPE="REFERENCE">le Roux 2012</LINK>; <LINK REF="REF-Mishra-2012" TYPE="REFERENCE">Mishra 2012</LINK>; <LINK REF="REF-Ntshoe-2013" TYPE="REFERENCE">Ntshoe 2013</LINK>; <LINK REF="REF-Pezzotti-2013" TYPE="REFERENCE">Pezzotti 2013</LINK>; <LINK REF="REF-Tricou-2013" TYPE="REFERENCE">Tricou 2013</LINK>) with significant morbidity.</P>
<CONDITION MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>At the beginning of 2000, it was estimated that each year measles infected 30 to 40 million people worldwide (<LINK REF="REF-Anonymous-2006" TYPE="REFERENCE">Anonymous 2006</LINK>). The annual reported incidence of measles decreased between 2000 and 2011 from 146 cases per million population to 52 per million population: a decline of 65%. Estimated measles deaths decreased from 548,300 to 157,700, amounting to a 71% decline. However, it is disturbing that between 2010 and 2011 widespread measles outbreaks have been reported in Africa, Europe, the Middle East and South East Asia (<LINK REF="REF-Anonymous-2013" TYPE="REFERENCE">Anonymous 2013</LINK>). In 2008, reported worldwide cases were at their lowest (278,417 cases). Since then reported cases have increased from 10,072 to 35,932 in the Middle East, from 186,675 to 194,364 in the South East Asian region and from 30,625 to 37,073 in European countries (<LINK REF="REF-Anonymous-2013" TYPE="REFERENCE">Anonymous 2013</LINK>). In France, over a period of four years, 22% of patients with measles required hospitalization and 12% developed complications, which included pneumonia (6.2%), acute otitis media (1.4%) hepatitis or pancreatitis (1.1%). Diarrhoea was reported in 100 cases (0.4%) (<LINK REF="REF-Antona-2013" TYPE="REFERENCE">Antona 2013</LINK>).</P>
<P>In South Africa almost 30% required hospitalization and the most common reason was pneumonia (68% of patients) (<LINK REF="REF-Ntshoe-2013" TYPE="REFERENCE">Ntshoe 2013</LINK>). Case-fatality rates of up to 20% have been documented in community studies in West Africa (<LINK REF="REF-Aaby-1984" TYPE="REFERENCE">Aaby 1984</LINK>). Current estimates of case-fatality rates used by the World Health Organization (WHO) in endemic countries range between 0.05% and 6% (<LINK REF="REF-Cairns-2010" TYPE="REFERENCE">Cairns 2010</LINK>). There are reports that severe measles worsens the nutritional status of the patient for several months following the acute episode (<LINK REF="REF-Bhaskaram-1984" TYPE="REFERENCE">Bhaskaram 1984</LINK>; <LINK REF="REF-Reddy-1986" TYPE="REFERENCE">Reddy 1986</LINK>) and increases morbidity and mortality (<LINK REF="REF-Kouadio-2010" TYPE="REFERENCE">Kouadio 2010</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>There is evidence that pneumonia in children with measles is often caused by bacterial infections. Histological features of bacterial pneumonia were found at autopsy in five out of 21 children in South Africa (<LINK REF="REF-Kaschula-1983" TYPE="REFERENCE">Kaschula 1983</LINK>). Bacterial pathogens as a cause of pneumonia have been isolated from lung puncture and tracheal aspirates (<LINK REF="REF-Dover-1975" TYPE="REFERENCE">Dover 1975</LINK>; <LINK REF="REF-Ellison-1931" TYPE="REFERENCE">Ellison 1931</LINK>; <LINK REF="REF-Gremillion-1981" TYPE="REFERENCE">Gremillion 1981</LINK>; <LINK REF="REF-Morton-1986" TYPE="REFERENCE">Morton 1986</LINK>; <LINK REF="REF-Olson-1975" TYPE="REFERENCE">Olson 1975</LINK>; <LINK REF="REF-Wesley-1971" TYPE="REFERENCE">Wesley 1971</LINK>). Observations at the Kingston Avenue Hospital, New York, suggested that 2.63% of 3611 children with measles died between 1935 and 1940, before antibiotics were administered, compared with only 0.74% of 1213 children in 1941, when sulfathiazole was first used (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>). A two-fold decline in measles-related case fatality was documented in Niakhar, a rural area of Senegal, when all children below three years of age were treated with a one-week course of cotrimoxazole if they were seen within two weeks of onset of illness (<LINK REF="STD-Samb-1995" TYPE="STUDY">Samb 1995</LINK>). The WHO subsequently proposed a randomized, double-blind, placebo-controlled trial of prophylactic antibiotics in measles as a priority for its research agenda (<LINK REF="REF-WHO-1995" TYPE="REFERENCE">WHO 1995</LINK>).</P>
<P>The risk factors associated with complications of measles and mortality include under nutrition (<LINK REF="REF-Caulfield-2004" TYPE="REFERENCE">Caulfield 2004</LINK>), young age, immune deficiency disorders, malnutrition, vitamin A deficiency, intense exposures to measles, lack of previous measles vaccination (<LINK REF="REF-Deivanayagam-1994" TYPE="REFERENCE">Deivanayagam 1994</LINK>; <LINK REF="REF-Perry-2004" TYPE="REFERENCE">Perry 2004</LINK>) and overcrowding (<LINK REF="REF-Burstr_x00f6_m-1999" TYPE="REFERENCE">Burström 1999</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>The evidence that pneumonia in children with measles is often caused by bacteria suggests that in countries with high case-mortality it might be appropriate to give antibiotics to all children with measles. However, a systematic review showed no evidence for such a policy (<LINK REF="REF-Shann-1997" TYPE="REFERENCE">Shann 1997</LINK>). A previous review found no evidence that routine prophylaxis prevents pneumonia developing in children with upper respiratory tract infections caused by other viruses (<LINK REF="REF-Gadomski-1993" TYPE="REFERENCE">Gadomski 1993</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>There have been multiple reports of outbreaks of measles in different parts of the world. In this context, it is important to review the role of prophylactic antibiotics in measles to prevent complications. The last update of this review in 2011 (<LINK REF="REF-Kabra-2011" TYPE="REFERENCE">Kabra 2011</LINK>) did not identify studies other than those included in the 2008 review (<LINK REF="REF-Kabra-2008" TYPE="REFERENCE">Kabra 2008</LINK>). However, in the 2011 review, the data were extracted again and the quality of all the included studies was assessed using The Cochrane Collaboration's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>).</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2013-06-28 14:02:01 +1000" MODIFIED_BY="[Empty name]">
<P>To assess the effects of antibiotics given to children with measles to prevent complications and reduce pneumonia, other morbidities and mortality.</P>
</OBJECTIVES>
<METHODS MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES MODIFIED="2011-04-12 12:29:55 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised controlled trials (RCTs) and quasi-RCTs comparing antibiotics with placebo or no treatment, to prevent complications in children with measles. Trials had to include the development of pneumonia as one of the outcome measures.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2008-02-20 09:56:47 +1000" MODIFIED_BY="[Empty name]">
<P>We included people younger than 18 years of age of either gender.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2008-02-20 09:57:05 +1000" MODIFIED_BY="[Empty name]">
<P>Oral or injectable antibiotics compared with no treatment or placebo.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2013-06-28 14:32:32 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Incidence of pneumonia.</LI>
</OL>
<P>The definition of pneumonia was based on either clinical or radiological criteria. The clinical criteria included rapid respiration, with or without auscultatory findings. Radiological criteria included features suggestive of infiltration, with or without consolidation, and with or without pleural effusion.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<OL>
<LI>Complications such as acute gastroenteritis, diarrhea, otitis media, tonsillitis and croup. Acute gastroenteritis was defined as the occurrence of loose stools with or without vomiting and with or without dehydration. Otitis media was diagnosed on the basis of otoscopic findings of an inflamed ear drum, with or without ear discharge. Tonsillitis was diagnosed on the findings of tonsillar enlargement with or without tender cervical adenitis. Croup was diagnosed as a sudden onset of hoarseness of the voice and a dry hacking cough, or a diagnosis of croup was mentioned by the authors.</LI>
<LI>Mortality.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>                                    </P>
<ELECTRONIC_SEARCHES MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>For this 2013 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) 2013, Issue 4, part of <I>The Cochrane Library,</I> www.thecochranelibrary.com (accessed 24 May 2013), which includes the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (2011 to May week 3, 2013) and EMBASE (2011 to May 2013). Details of previous searches are in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We searched MEDLINE using keywords and MeSH terms in conjunction with the Cochrane Highly Sensitive Search Strategy for identifying randomized trials in MEDLINE: sensitivity- and precision-maximising version (2008 revision); Ovid format (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>) (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We used the same strategy to search CENTRAL and adapted it to search EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>). We did not use any publication, language or date limitations.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2013-05-31 13:05:21 +1000" MODIFIED_BY="[Empty name]">
<P>We searched ClinicalTrials.gov and WHO ICTRP for new and ongoing trials (24 March 2013). We checked all relevant cross-references of studies included in the review.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>We obtained full-text articles with the help of the Cochrane Acute Respiratory Infections (ARI) Group. We gave the papers a serial number. Two review authors (SKK, RL) independently reviewed the results for inclusion in the analysis. We resolved differences about study quality through discussion. We recorded data on a pre-structured data extraction form. We collected data on the primary outcome (development of pneumonia) and secondary outcomes (development of acute gastroenteritis, diarrhea, otitis media, tonsillitis and croup, as well as mortality). We performed sensitivity analysis to check the importance of each study in order to see the effect of the inclusion and exclusion criteria. We computed both the effect size and summary measures with 95% confidence intervals (CIs) using RevMan 5.2 (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>) software. We used a random-effects model to combine the study results for all the outcome variables.</P>
<STUDY_SELECTION MODIFIED="2011-06-27 00:19:15 +1000" MODIFIED_BY="[Empty name]">
<P>Two authors (SKK, RL) checked the abstracts of all the relevant studies. The authors independently read the full texts of those suggestive of a RCT using antibiotic prophylaxis. We selected studies in children below 18 years of age, using post-measles antibiotic prophylaxis and describing pneumonia as one of the outcomes. There was no disagreement between the authors on selection of the studies.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>We prepared a form for data extraction. Two authors (RL, SKK) independently extracted data from full-text articles. We obtained details of unclear data from authors of recent reports. One author (SKK) entered data into RevMan 5.2. Some of the data were unclear from one study; after resolving the differences by discussion, we entered the data.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed publication bias using The Cochrane Collaboration's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We attempted to assess risk of bias by checking for adequate sequence generation, allocation concealment, blinding, incomplete outcome data addressed, and whether free of selective reporting and other bias.</P>
<SUBSECTION>
<HEADING LEVEL="3">1. Sequence generation: assessed as high risk, low risk or unclear</HEADING>
<P>Low risk: when the study described the method used to generate the allocation sequence in sufficient detail.<BR/>High risk: sequence not generated.<BR/>Unclear: when it was not described or incompletely described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">2. Allocation concealment: assessed as high risk, low risk or unclear</HEADING>
<P>Low risk: when the study described the method used to conceal the allocation sequence in sufficient detail.<BR/>High risk: described where allocation concealment was not done.<BR/>Unclear: when it was not described or incompletely described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">3. Blinding of participants, personnel and outcome assessors: assessed as high risk, low risk or unclear</HEADING>
<P>Low risk: when it was a double-blind study.<BR/>High risk: when it was an unblinded study.<BR/>Unclear: not clearly described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">4. Incomplete outcome data: assessed as high risk, low risk or unclear</HEADING>
<P>Low risk: describe the completeness of outcome data for each main outcome, including attrition and exclusions from the analysis.<BR/>High risk: not described.<BR/>Unclear: incompletely described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">5. Free of selective outcome reporting: assessed as high risk, low risk or unclear</HEADING>
<P>Low risk: results of study free of selective reporting. Details of all the patients enrolled in the study are included in the paper.<BR/>High risk: details of all the enrolled patients not given in the paper.<BR/>Unclear: details of all the enrolled patients incompletely described.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">6. Other sources of bias</HEADING>
<P>Among the other sources of potential bias we considered was funding agencies and their role in the study. We recorded funding agencies or pharmaceutical companies. We considered studies supported by pharmaceutical companies to be unclear unless the study defined the role of the pharmaceutical companies. We also considered studies not mentioning the source of funding as unclear under this heading.</P>
</SUBSECTION>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>The primary outcome variable was development of pneumonia in children with measles. We calculated the odds ratio (OR) for assessing risk for development of pneumonia.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2013-08-14 08:39:13 +1000" MODIFIED_BY="[Empty name]">
<P>We included only randomized controlled trials (RCTs) and quasi-RCTs comparing antibiotics with placebo or no treatment, to prevent complications of measles in children. For studies having multiple treatment groups, we combined all those receiving antibiotics in one arm and those receiving placebo or no treatment in another arm, when the outcome assessed was similar.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>We attempted to contact the trial authors for missing data. However, we were successful for only one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). This study included all age groups (children and adults) and, on request, the trial authors provided details of patients below 18 years of age. We were unable to contact the trial authors of six very old studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>We examined the homogeneity of effect sizes between pooled studies with the I<SUP>2</SUP> statistic, using 25% or more as a cut-off for exploring possible causes of heterogeneity (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). We used a two-by-two table for each study and performed Breslow's test of homogeneity to determine variation in study results for each of the outcome variables. In case of heterogeneity between the studies, we made efforts to explore the causes. We described the intervention effects using a random-effects model throughout as there was significant heterogeneity between the studies for some of the outcomes (as evaluated by the I<SUP>2 </SUP>statistic).</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2011-04-14 10:57:19 +1000" MODIFIED_BY="[Empty name]">
<P>We assessed reporting biases for the studies by using funnel plots.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2011-06-26 23:55:51 +1000" MODIFIED_BY="[Empty name]">
<P>We described the intervention effects using a random-effects model throughout as there was significant heterogeneity between the studies for some of the outcomes (as evaluated by the I<SUP>2 </SUP>statistic).</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2011-04-18 11:14:36 +1000" MODIFIED_BY="[Empty name]">
<P>None.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2011-03-24 14:12:34 +1000" MODIFIED_BY="[Empty name]">
<P>We performed a sensitivity analysis to check the importance of each study in order to see the effect of inclusion and exclusion criteria. We computed both the effect size and summary measures with 95% confidence intervals (CI).</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<STUDY_DESCRIPTION MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<SEARCH_RESULTS MODIFIED="2013-08-14 08:31:15 +1000" MODIFIED_BY="Liz Dooley">
<P>Our searches were updated in May 2013 but we did not identify any new trials for inclusion.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<P>We included seven controlled clinical trials on the use of antibiotics to prevent complications in children with measles. Five studies were conducted in Glasgow, London and New York between 1939 and 1954. One study was conducted in India in the 1960s and a more recent one in Bissau, Guinea-Bissau, West Africa, was published in 2006.</P>
<P>The details of studies included in the review are as follows and also shown in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK>.</P>
<P>The <LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK> study included 125 children (62 in the control group and 63 in the intervention group) under six years of age. The intervention included administration of sulphanilamide for 10 days or no drug to alternate patients. This was a hospital-based study. Some of the patients already had complications such as pneumonia, otitis media etc. However, separate data for those without complications were not available in the paper. The total number of patients allocated to each group was computed by subtracting the numbers who already had complications at enrolment. Therefore, for pneumonia the number of children who were allocated to antibiotics was counted as 47 (as 16 had pneumonia at the time of enrolment) and in the control group the total enrolled without pneumonia was 49. There was no allocation concealment.</P>
<P>The <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK> study included 329 children (170 in the intervention group and 159 in the control group). The intervention included administration of para-benzylaminobenzenesulphonamide for 10 days or no treatment to alternate patients. The groups were comparable and there was no allocation concealment.</P>
<P>The <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK> study included 354 children below six years of age (201 in the control group and 153 in the intervention group). The intervention included administration of oral sulfathiazole until discharge or symptomatic treatment but no antibiotics. The participants were divided into two groups at the time of admission to hospital. The precise methods of randomization and allocation concealment were not mentioned in the trial. Separate data for those who already had pneumonia were not mentioned in the paper. However, the numbers of uncomplicated cases (we presume children without pneumonia) in the intervention and control groups at the time of enrolment were 82 and 148, respectively.</P>
<P>The <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK> study enrolled 132 children below nine years of age admitted to hospital. The intervention included administration of chlortetracycline (Aureomycin) (45 children), penicillin (44 children) and no active treatment (43 children). The first 15 participants received antibiotics followed by alternate allocation to receive no active intervention. The method of randomization or allocation concealment was not described by the trial authors. For the purpose of comparison, we analyzed the penicillin and chlortetracycline groups together. No patients in either group had pneumonia at time of enrolment therefore the total number of patients available for assessment of the primary outcome (pneumonia) was 89 for the intervention group and 43 for the control group.</P>
<P>The <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK> study enrolled 256 children below 10 years of age. The intervention included the administration of a single dose of Benzethacil (61 participants), aqueous procaine penicillin (67 participants) for four days or aqueous procaine penicillin on day 0, 3 and day 6 (47 participants). The control group (81 participants) did not receive any antibiotics. There was no allocation concealment. For the purpose of analysis, children receiving benzathine penicillin (61) and four doses of aqueous procaine penicillin (67) and those receiving three doses of aqueous procaine penicillin (47 participants) were analyzed together to form the intervention group (175). In the intervention group 19 patients already had pneumonia. Therefore the number of children available for assessment of the primary outcome (pneumonia) was 156 in the intervention group and 81 in the control group.</P>
<P>The <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK> study enrolled 158 children (80 in the control group and 78 in the intervention group). Intervention included administration of placebo or tetracycline for seven days. The study included participants admitted to hospital as well as ambulatory participants. There was no mention of loss to follow-up.</P>
<P>We obtained additional data on children less than 18 years of age from the authors of the <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK> study as the published study gave data for participants less than 25 years of age. The Garly study enrolled 81 participants with measles below 18 years of age during a measles epidemic in Bissau in 1998. Interventions included sulfamethoxazole-trimethoprim (co-trimoxazole (N = 44)) or placebo for seven days (N = 37). This was a randomized, double-blind, placebo-controlled trial; this is the only methodologically sound trial.</P>
<P>None of the included studies used vitamin A in children with measles.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>Three published studies were excluded from the review because they were not controlled trials. <LINK REF="STD-Thompson-1938" TYPE="STUDY">Thompson 1938</LINK> reported that 1.7% of 352 children treated with an antibiotic and 4.8% of 762 controls developed bronchopneumonia. On the other hand, <LINK REF="STD-Weinstein-1955" TYPE="STUDY">Weinstein 1955</LINK> found pneumonia at the time of admission to hospital in 21.5% of 130 children who had been treated with an antibiotic and 8.1% of 298 children who had not had an antibiotic. In Senegal the case-mortality from measles fell substantially after an increase in measles immunisation and administration of co-trimoxazole to all children less than three years of age who had measles (<LINK REF="STD-Samb-1995" TYPE="STUDY">Samb 1995</LINK>). See <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK>.</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<P>All but two studies were unblinded (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>) and only two studies mentioned withdrawals from the trial (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). Only one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>) provided information about antibiotic treatment given before randomization and these children were not enrolled in the study. We assessed the quality of studies using The Cochrane Collaboration's 'Risk of bias' tool (<LINK REF="REF-Higgins-2011" TYPE="REFERENCE">Higgins 2011</LINK>). The overall risk of bias is presented graphically in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and summarised in <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2011-04-14 12:10:19 +1000" MODIFIED_BY="[Empty name]">
<P>Generation of allocation sequence and concealment was described in two studies (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>). In the remaining five studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>) it was not very clear.</P>
</ALLOCATION>
<BLINDING MODIFIED="2011-04-14 12:10:47 +1000" MODIFIED_BY="[Empty name]">
<P>Blinding was done in two studies only (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>). All other studies were not blinded.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<P>Outcome data on all the patients who did not have pneumonia at time of enrolment were available in one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). In other studies, data were extracted from available information. They randomized children with complications. Separate data for those who did not have complications and those who had complications were not clearly defined in six studies.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2011-05-11 09:26:00 +1000" MODIFIED_BY="Liz Dooley">
<P>All but one study reported outcomes completely (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>).</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>One study received support for blood analysis from the Medical Research Council Laboratory in Gambia (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). Two studies (<LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>) received support in the form of drugs from pharmaceutical companies. However, the role in the trials is not clearly defined. Funding sources could not be identified in the rest of the studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2013-08-14 08:39:16 +1000" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="3">Primary outcome</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Incidence of pneumonia</HEADING>
<P>A total of seven studies including 1263 children (654 in the intervention group and 609 in the control group) were included in the study. A total of 86 children (27 in the intervention group and 59 in the control group) developed pneumonia. Two studies (<LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>) showed a significant reduction in the incidence of pneumonia, while one study (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>) showed an increased incidence. In four studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>) there was a decrease in the incidence of pneumonia but it did not reach statistical significance. Pooled study data showed that the incidence of pneumonia was lower in the treatment group compared to the control group. Out of 654 children who received antibiotics, 27 (4.1%) developed pneumonia, while out of 609 children in the control group, 59 (9.6%) developed pneumonia (odds ratio (OR) 0.35; 95% confidence interval (CI) 0.12 to 1.01) (<LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK>). All the studies showed a decrease in the incidence of pneumonia with the use of antibiotics, except one study (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>). This study included 230 children (82 in the intervention group and 148 in the control group). Six children out of 82 developed pneumonia in the intervention group as compared to no pneumonia in 148 children who received only supportive care. If the results of this study (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>) are dropped from the analysis, there is a significant reduction in the occurrence of pneumonia in children receiving antibiotics (OR 0.26; 95% CI 0.12 to 0.60) (<LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>)</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Secondary outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">1. Complications</HEADING>
<SUBSECTION>
<HEADING LEVEL="5">Diarrhoea</HEADING>
<P>Data on the development of diarrhea were available in four studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>). There was no significant effect on the development of diarrhea with antibiotics (OR 0.53; 95% CI 0.23 to 1.22) (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>). In the <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK> study, two children in the antibiotic group developed diarrhea compared with five children in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Conjunctivitis</HEADING>
<P>Data on the development of conjunctivitis were available in two studies (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>). There was no significant difference in the development of conjunctivitis in the two groups (OR 0.39; 95% CI 0.15 to 1.0) (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). In the <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK> study, 11 children in the antibiotic group developed conjunctivitis compared to 17 children in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Otitis media</HEADING>
<P>Data on purulent otitis media were available in five studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>). Two studies reported catarrhal otitis media; these data were not included in the analysis. The incidence of otitis media was lower in children treated with antibiotics (OR 0.34; 95% CI 0.16 to 0.73) (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>). Of the 1.8% of children who received antibiotics, 5.3% developed purulent otitis media. None of the studies were found to alter the results in the other direction when the analysis was done by dropping one study at a time. In the <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK> study one child in the antibiotic group developed otitis media compared with two children in the placebo group.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Croup</HEADING>
<P>Data on the development of croup were available in one study (<LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>) and there was no significant difference between the two groups (OR 0.16; 95% CI 0.01 to 4.06) (<LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="5">Tonsillitis and pharyngitis</HEADING>
<P>Data on the development of tonsillitis or pharyngitis were available in two studies<B> </B>(<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>) and showed a reduction in the incidence of tonsillitis in children receiving antibiotics (OR 0.08; 95% CI 0.01 to 0.72) (<LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK>).</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">2. Mortality</HEADING>
<P>The mortality rate was 0.49% in children receiving antibiotics compared to 0.14% in the control group. The difference was not significant (OR 3.04; 95% CI 0.47 to 19.63) (<LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>). In the <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK> study, no deaths were reported.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Baseline characteristics of participants</HEADING>
<P>The median age of participants in the control and intervention groups was not provided in all of the studies. The number of children below two years of age was available in five studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>). The groups were not equally distributed - in the intervention group there were more children below two years of age (OR 1.50; 95% CI 1.18 to 1.92).</P>
<P>Gender distribution was described separately for the two groups in three studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>) and was comparable in two groups (OR 1.15; 95% CI 0.69 to 1.91). The nutritional status was available in one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>) and it was comparable (OR 2.73; 95% CI 0.97 to 7.71) in the two groups.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Side effects of antibiotics</HEADING>
<P>Side effects attributable to the study drugs were specifically reported in two studies (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>). Two children developed erythema nodosum after receiving sulfathiazole (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>). In the other study (<LINK REF="STD-Karelitz-1951" TYPE="STUDY">Karelitz 1951</LINK>), 13 children developed vomiting after administration of chlortetracycline two to three days after initiation of treatment and three children developed diarrhea; both side effects were self limiting and did not require discontinuation of therapy. Five studies (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>; <LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>; <LINK REF="STD-Karelitz-1954" TYPE="STUDY">Karelitz 1954</LINK>; <LINK REF="STD-Prasad-1967" TYPE="STUDY">Prasad 1967</LINK>) did not report any specific side effects attributable to the study drugs.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<P>This systematic review suggests that antibiotics administered to children with measles decrease the incidence of otitis media and tonsillitis and show a trend towards decreasing the incidence of pneumonia (OR 0.35; 95% CI 0.12 to 1.01). One study (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>) that showed an increase in pneumonia was removed in a sensitivity analysis which resulted in a statistically significant reduction in the rate of pneumonia. </P>
<P>Given the overall results, however, this result cannot be relied upon and further trials are necessary to confirm the beneficial effects seen, particularly in the latest and most rigorous trial. Similarly, to prevent one case of otitis media, we need to treat 24 patients. Antibiotics did not affect the development of diarrhea, conjunctivitis, croup or mortality. Only one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>) was a well-conducted randomized controlled trial (RCT); the remaining six studies scored poorly in quality assessment. In a pooled analysis, all the studies favoured the treatment group for prevention of pneumonia except for the <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK> study; the effect size reached significance when the <LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK> study was dropped from the analysis. In the Gibel study, a total of 153 children were enrolled in the treatment group compared to 201 in the no treatment group; however, the numbers of uncomplicated cases (we presume children without pneumonia) in the intervention and control groups at the time of enrolment were 82 and 148, respectively. The number of children below two years of age was higher in the treatment group compared to the no treatment group (64 versus 45). Separate data for the development of pneumonia in children below two years of age were not available. Age is one of the risk factors for pneumonia; as the participants were young, age may have affected the results in this study.</P>
<P>Of the seven studies included in the review, only one (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>) provided data on malnutrition. In this study, the number of children with a weight for age z-score of below -2 was higher in the intervention group compared to the control group. However, the incidence of pneumonia was higher in the control group, suggesting a benefit from cotrimoxazole in malnourished children. In other studies, data on the distribution of malnourished children in the two groups were not available.</P>
<P>Children who develop measles below two years of age have a higher incidence of diarrhea, pneumonia and otitis media (<LINK REF="REF-Deivanayagam-1994" TYPE="REFERENCE">Deivanayagam 1994</LINK>; <LINK REF="REF-Perry-2004" TYPE="REFERENCE">Perry 2004</LINK>). The number of children below two years of age was higher in the antibiotics group compared to the control group in this review. Although we could not find an analysis of children below two years of age and above two years for the development of different morbidities, the incidence of pneumonia and otitis media was significantly lower in the treatment group compared to the control group, indirectly suggesting benefits from antibiotics in the younger age group.</P>
<P>Data on immune deficiency, vitamin A deficiency, intense exposure to measles and a lack of measles vaccination were not available in the included studies and therefore could not be compared in this review.</P>
<P>The only other intervention that may improve the outcome in children with measles is the supplementation of two doses of vitamin A (200,000 IU) on consecutive days. This was associated with a reduction in the risk of mortality in children under the age of two years (risk ratio (RR) 0.21; 95% CI 0.07 to 0.66) and a reduction in the risk of pneumonia-specific mortality (RR 0.57; 95% CI 0.24 to 1.37) (<LINK REF="REF-Yang-2011" TYPE="REFERENCE">Yang 2011</LINK>).</P>
<P>The main limitation of this review was that the seven controlled trials included a total of 1385 children with a relatively low number of complications (54 cases of pneumonia, 40 of diarrhea, 28 of conjunctivitis, 36 of otitis media and five deaths). Only one trial was of good quality and the other six trials were poorly designed; randomization was not described or was by alternate allocation, all but two were unblinded and little information was provided about withdrawals. Only one of the trials (<LINK REF="STD-Anderson-1939" TYPE="STUDY">Anderson 1939</LINK>) had a mortality of 1% or more, although two others (<LINK REF="STD-Gibel-1942" TYPE="STUDY">Gibel 1942</LINK>; <LINK REF="STD-Hogarth-1939" TYPE="STUDY">Hogarth 1939</LINK>) were conducted in communities where the mortality had been more than 1% in the immediately preceding years, when antibiotics were not available. The selection of cases for antibiotics in these trials was not very strict. Even though we tried to include only those children without complications at the time of study enrolment, we cannot be absolutely sure about the 'contamination' of groups. It appears that the children were observed only for a limited period of time, for example, during the hospital stay; only one study observed children up to one month (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). The other important limitation of the review is that most of the studies were carried out before the introduction of vitamin A. Since vitamin A may influence the outcome of measles, including the development of morbidities, more studies are needed to evaluate the efficacy of antibiotics in association with vitamin A.</P>
<P>The diagnosis of measles was made on a clinical basis in the majority of patients analyzed in the review. Serological diagnostic confirmation of measles was attempted in one study (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>). The use of clinical criteria only to diagnose measles may have lead to the inclusion of bacterial infections that mimic measles.</P>
<P>A variety of antibiotics such as sulphonamide, penicillin, tetracycline and co-trimoxazole were used. All the studies except one were conducted before 1970. The effect of antibiotics will depend on the organisms and their sensitivity patterns. Whether newer antibiotics will give similar results remains to be seen. Also, there was variability in the time antibiotics were started and the duration of treatments. Most studies used antibiotics for a duration of up to 10 days or until discharge from hospital. These observations prevent the review authors from recommending a particular antibiotic regimen to prevent complications of measles. The most recent study included in the review (<LINK REF="STD-Garly-2006" TYPE="STUDY">Garly 2006</LINK>) used co-trimoxazole and found it to be effective. Among the antibiotics used in earlier studies that are still used in clinical practice, penicillin was also effective.</P>
<P>The studies reviewed here provide evidence that administration of antibiotics in children with measles reduces the incidence of pneumonia, otitis media and tonsillitis. There was no effect on death rates, conjunctivitis, croup or diarrhea.</P>
<SUMMARY_OF_RESULTS MODIFIED="2011-04-14 14:07:11 +1000" MODIFIED_BY="[Empty name]">
<P>In this review, we included seven clinical trials; studies were of poor quality except for one RCT. All the studies used less effective antimicrobial agents. The time and schedule of administration of antibiotics was variable. Results suggest that antibiotics after development of measles may reduce the incidence of otitis media and tonsillitis. However, the reduction in incidence of pneumonia is not significant. From the present evidence it is difficult to suggest drug, dose and timings of administration of antibiotics for children with measles.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>The present set of evidence is not sufficient for recommending the use of antibiotics for reducing complications in children with measles.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<P>The quality of evidence is poor and only two studies were randomized, double-blind trials. There was variation in the antibiotics used, their doses, schedule and evaluation of outcome. Therefore, no recommendations can be made from the current evidence.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>All the available studies were included for review. We tried to search published literature as completely as possible; we retrieved full-text articles for studies published in the 1930s and 1940s. There was significant heterogeneity. We tried to check for publication bias using a funnel plot. We performed a sensitivity analysis to see the effect of each study on the main outcome. The studies included children who had already developed complications before enrolment in the study. We tried to exclude children who had pneumonia at the time of enrolment from analysis of the primary outcome. Clarification about the data or incomplete data could not be obtained from authors, except in one study, as most studies were carried out before 1960. The quality of reporting and analysis was poor by today's standard.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2013-06-28 14:25:39 +1000" MODIFIED_BY="[Empty name]">
<P>The findings are in agreement with the other reviews on the subject (<LINK REF="REF-Shann-1997" TYPE="REFERENCE">Shann 1997</LINK>)</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<IMPLICATIONS_PRACTICE MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]">
<P>Measles is a public health problem in some parts of the world. This review suggests that there is a beneficial effect of antibiotic administration for children with measles in reducing the incidence of complications such as pneumonia, otitis media and tonsillitis. There is no consensus as to the type of antibiotics, duration, time of antibiotic initiation or dosage in this review, although penicillin and co-trimoxazole were found to be effective. There is a need to generate more data from well-planned randomized controlled trials (RCTs) to answer these questions.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2013-06-28 14:28:06 +1000" MODIFIED_BY="[Empty name]">
<P>This review suggests a benefit in giving antibiotics to children with measles to reduce complications. In view of the heterogeneity of the interventions and the poor methodological quality of most of the included studies (conducted more than five decades ago), there is a need for well-designed RCTs to evaluate the effect of antibiotics in reducing pneumonia and other morbidities. Further trials are needed to evaluate the type and duration of antibiotics which are known to be effective. Available evidence suggests that two doses of vitamin A given to children below two years of age with measles may reduce mortality. However, none of the studies in this review gave vitamin A to children with measles. Vitamin A may modify the course of the illness and therefore there is a need to include vitamin A administration while conducting clinical trials for post-measles complications.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2013-08-09 22:58:47 +1000" MODIFIED_BY="[Empty name]">
<P>We acknowledge the authors of the original Cochrane Review: Frank Shann, Rennie D'Souza and Ron D'Souza; the help provided by the All India Institute of Medical Sciences, New Delhi, in providing access to the Internet; help provided by Liz Dooley (Managing Editor) and Sarah Thorning (Trials Search Co-ordinator) with conducting the EMBASE search and obtaining full-text articles; and Dr RM Pandey, Department of Biostatistics, All India Institute of Medical Sciences, New Delhi for statistical advice. We acknowledge the contributions of Deborah J Hilton in the last update of this review (<LINK REF="REF-Kabra-2008" TYPE="REFERENCE">Kabra 2008</LINK>).</P>
<P>We acknowledge Sarah Thorning (Trial Search Co-ordinator for the ARI Group) for doing the EMBASE search for this latest update. Thanks also to the following for commenting on previous drafts: Irénée Domkam Kammogne, Cheryl Flynn, Mark Jones and Jenny Doust.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-06-28 14:29:29 +1000" MODIFIED_BY="[Empty name]">
<P>None of the review authors have any conflicts of interest to declare in this review.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2011-06-27 00:05:41 +1000" MODIFIED_BY="[Empty name]">
<P>This review was updated by SK Kabra and R Lodha.<BR/>SK Kabra (SKK) and R Lodha (RL) conducted the literature searches and reviewed and compiled data from the studies included in the update of this review.<BR/>SKK and RL wrote the review update.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2013-06-28 14:29:38 +1000" MODIFIED_BY="[Empty name]">
<P>No differences.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2013-06-28 14:30:01 +1000" MODIFIED_BY="[Empty name]">
<P>This review, formerly titled 'Antibiotics for preventing pneumonia in children with measles' was withdrawn from <I>The Cochrane Library</I>, 2006, Issue 3 as the review authors could no longer update it. It was taken over by a new team of authors in 2006 and completed in March 2008. In this update the title of the review was changed to 'Antibiotics for preventing complications in children with measles', as complications other than pneumonia were also evaluated. </P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Anderson-1939" NAME="Anderson 1939" YEAR="1939">
<REFERENCE NOTES="&lt;p&gt;Anderson T. Sulphanilamide in the treatment of measles. BMJ 1939;i:716-8.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anderson T</AU>
<TI>Sulphanilamide in the treatment of measles</TI>
<SO>British Medical Journal</SO>
<YR>1939</YR>
<VL>i</VL>
<PG>716-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garly-2006" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Garly 2006" YEAR="2006">
<REFERENCE MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Garly M, Bal&amp;#233; C, Martins LC, Whittle HC, Nielsen J, Lisse IM, Aaby P. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau&lt;br&gt;BMJ. 2006 Dec 16;333(7581):1245. Epub 2006 Oct 23. &lt;/p&gt;&lt;p&gt;&lt;br&gt; BMJ, doi:10.1136/bmj.38989.684178.AE (published 23 October 2006)&lt;br&gt;&lt;/p&gt;" NOTES_MODIFIED="2013-08-09 21:29:39 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garly M, Balé C, Martins LC, Whittle HC, Nielsen J, Lisse IM, et al</AU>
<TI>Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau</TI>
<SO>BMJ</SO>
<YR>2006</YR>
<VL>333</VL>
<NO>7581</NO>
<PG>1245</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gibel-1942" NAME="Gibel 1942" YEAR="1942">
<REFERENCE NOTES="&lt;p&gt;Gibel H, Litvak AM. Sulfathiazole in the treatment of measles and its complications. J Pediatr 1942;21:315-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gibel H, Litvak AM</AU>
<TI>Sulfathiazole in the treatment of measles and its complications</TI>
<SO>Journal of Pediatrics</SO>
<YR>1942</YR>
<VL>21</VL>
<PG>315-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hogarth-1939" NAME="Hogarth 1939" YEAR="1939">
<REFERENCE NOTES="&lt;p&gt;Hogarth JC. Para-benzylaminobenzenesulphonamide in the prevention of measles complications. BMJ 1939;i:718-20.&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hogarth JC</AU>
<TI>Para-benzylaminobenzenesulphonamide in the prevention of measles complications</TI>
<SO>British Medical Journal</SO>
<YR>1939</YR>
<VL>i</VL>
<PG>718-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karelitz-1951" MODIFIED="2011-04-14 14:55:13 +1000" MODIFIED_BY="[Empty name]" NAME="Karelitz 1951" YEAR="1951">
<REFERENCE MODIFIED="2011-04-14 14:55:13 +1000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karelitz S, King H, Curtis B, Wechsel M</AU>
<TI>Use of aureomycin and penicillin in the treatment of rubeola in the pre-eruptive and early eruptive phase</TI>
<SO>Pediatrics</SO>
<YR>1951</YR>
<VL>7</VL>
<PG>193-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karelitz-1954" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Karelitz 1954" YEAR="1954">
<REFERENCE MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Karelitz S, Chang C, Matthews ZE. The prophylaxis and treatment of bacterial complications of measles with benzethacil and aqueous procaine penicillin G. J Pediatr 1954;44:357-63.&lt;/p&gt;" NOTES_MODIFIED="2013-08-09 21:29:39 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karelitz S, Chang C, Matthews ZE</AU>
<TI>The prophylaxis and treatment of bacterial complications of measles with benzethacil and aqueous procaine penicillin G</TI>
<SO>Journal of Pediatrics</SO>
<YR>1954</YR>
<VL>44</VL>
<PG>357-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prasad-1967" MODIFIED="2008-03-25 14:39:45 +1000" MODIFIED_BY="[Empty name]" NAME="Prasad 1967" YEAR="1967">
<REFERENCE MODIFIED="2008-03-25 14:39:45 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Prasad R, Mathur GP, Trehan OP, Mehrotra, Dayal RS. A clinical and radiological study of measles. Indian Pediatr 1967;4:243-50.&lt;/p&gt;" NOTES_MODIFIED="2008-03-25 14:39:45 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prasad R, Mathur GP, Trehan OP, Mehrotra ML, Dayal RS</AU>
<TI>A clinical and radiological study of measles</TI>
<SO>Indian Pediatrics</SO>
<YR>1967</YR>
<VL>4</VL>
<PG>243-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-02-21 09:57:35 +1000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Samb-1995" NAME="Samb 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Samb B; Simondon F; Aaby P; Whittle H; Seck AM. Prophylactic use of antibiotics and reduced case fatality in measles infection. Pediatr Infect Dis J, 14:695-6, 1995&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Samb B, Simondon F, Aaby P, Whittle H, Seck AM</AU>
<TI>Prophylactic use of antibiotics and reduced case fatality in measles infection</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1995</YR>
<VL>14</VL>
<PG>695-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1938" MODIFIED="2008-02-21 09:57:35 +1000" MODIFIED_BY="[Empty name]" NAME="Thompson 1938" YEAR="1938">
<REFERENCE MODIFIED="2008-02-21 09:57:35 +1000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Thompson AR, Greenfield CRM. Chemotherapy in measles and whooping-cough: prophylaxis and treatment of complications. Lancet 1938; 2: 991-4&lt;/p&gt;" NOTES_MODIFIED="2008-02-21 09:57:35 +1000" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Thompson AR, Greenfield CRM</AU>
<TI>Chemotherapy in measles and whooping-cough: prophylaxis and treatment of complications</TI>
<SO>Lancet</SO>
<YR>1938</YR>
<VL>2</VL>
<PG>991-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Weinstein-1955" NAME="Weinstein 1955" YEAR="1955">
<REFERENCE NOTES="&lt;p&gt;Weinstein L. Failure of chemotherapy to prevent the bacterial complications of measles. N Engl J Med 1955; 253: 679-82&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Weinstein L</AU>
<TI>Failure of chemotherapy to prevent the bacterial complications of measles</TI>
<SO>New England Journal of Medicine</SO>
<YR>1955</YR>
<VL>253</VL>
<PG>679-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Aaby-1984" MODIFIED="2008-03-13 10:58:45 +1000" MODIFIED_BY="Liz Dooley" NAME="Aaby 1984" NOTES="&lt;p&gt;Aaby P, Bukh J, Lisse IM, et al. Overcrowding and intensive exposure as determinants of measles mortality. Am J Epidemiol 1984; 120: 49-63.&lt;/p&gt;" NOTES_MODIFIED="2008-03-13 10:58:45 +1000" NOTES_MODIFIED_BY="Liz Dooley" TYPE="JOURNAL_ARTICLE">
<AU>Aaby P, Bukh J, Lisse IM, Smits AJ</AU>
<TI>Overcrowding and intensive exposure as determinants of measles mortality</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1984</YR>
<VL>120</VL>
<PG>49-63</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1984253708"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2002" NAME="Anonymous 2002" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Global measles mortality reduction and regional elimination, 2000-2001: part I</TI>
<SO>Weekly Epidemiologic Records</SO>
<YR>2002</YR>
<VL>77</VL>
<PG>50-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2006" MODIFIED="2011-04-14 14:55:45 +1000" MODIFIED_BY="[Empty name]" NAME="Anonymous 2006" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Progress in reducing global measles deaths: 1999-2004</TI>
<SO>Weekly Epidemiologic Records</SO>
<YR>2006</YR>
<VL>10</VL>
<PG>90-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anonymous-2013" MODIFIED="2013-06-20 00:54:25 +1000" MODIFIED_BY="[Empty name]" NAME="Anonymous 2013" TYPE="JOURNAL_ARTICLE">
<AU>Anonymous</AU>
<TI>Progress in global control and regional elimination of measles, 2000&#8211;2011</TI>
<SO>Weekly Epidemiology Records</SO>
<YR>2013</YR>
<VL>88</VL>
<PG>29-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Antona-2013" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Antona 2013" TYPE="JOURNAL_ARTICLE">
<AU>Antona D, Lévy-Bruhl D, Baudon C, Freymuth F, Lamy M, Maine C, et al</AU>
<TI>Measles elimination efforts and 2008-2011 outbreak, France</TI>
<SO>Emerging Infectious Diseases</SO>
<YR>2013</YR>
<VL>19</VL>
<PG>357-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bandyopadhyay-2013" MODIFIED="2013-08-09 21:17:46 +1000" MODIFIED_BY="[Empty name]" NAME="Bandyopadhyay 2013" TYPE="JOURNAL_ARTICLE">
<AU>Bandyopadhyay AS, Bandy U</AU>
<TI>Emerging global epidemiology of measles and public health response to confirmed case in Rhode island</TI>
<SO>Rhode Island Medical Journal</SO>
<YR>2013</YR>
<VL>96</VL>
<PG>41-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bhaskaram-1984" MODIFIED="2008-03-13 10:59:59 +1000" MODIFIED_BY="Liz Dooley" NAME="Bhaskaram 1984" NOTES="&lt;p&gt;Bhaskaram P, Reddy V, Raj S, et al. Effect of measles on the nutritional status of preschool children. J of Trop Med Hyg 1984; 87: 21-5.&lt;/p&gt;" NOTES_MODIFIED="2008-03-13 10:59:59 +1000" NOTES_MODIFIED_BY="Liz Dooley" TYPE="JOURNAL_ARTICLE">
<AU>Bhaskaram P, Reddy V, Raj S, Bhatnagar RC</AU>
<TI>Effect of measles on the nutritional status of preschool children</TI>
<SO>Journal of Tropical Medicine and Hygiene</SO>
<YR>1984</YR>
<VL>87</VL>
<PG>21-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Burstr_x00f6_m-1999" MODIFIED="2008-03-03 11:29:01 +1000" MODIFIED_BY="[Empty name]" NAME="Burström 1999" TYPE="JOURNAL_ARTICLE">
<AU>Burström B, Diderichsen F, Smedman L</AU>
<TI>Child mortality in Stockholm during 1885-1910: the impact of household size and number of children in the family on the risk of death from measles</TI>
<SO>American Journal of Epidemiology</SO>
<YR>1999</YR>
<VL>149</VL>
<PG>1134-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cairns-2010" MODIFIED="2011-04-19 14:56:51 +1000" MODIFIED_BY="[Empty name]" NAME="Cairns 2010" TYPE="JOURNAL_ARTICLE">
<AU>Cairns KL, Nandy R, Grais RF</AU>
<TI>Challenges in measuring measles case fatality ratios in settings without vital registration</TI>
<SO>Emerging Themes in Epidemiology</SO>
<YR>2010</YR>
<VL>7</VL>
<NO>1</NO>
<PG>4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Caulfield-2004" MODIFIED="2008-03-14 16:57:37 +1000" MODIFIED_BY="[Empty name]" NAME="Caulfield 2004" TYPE="JOURNAL_ARTICLE">
<AU>Caulfield LE, de Onis M, Blössner M, Black RE</AU>
<TI>Undernutrition as an underlying cause of child deaths associated with diarrhea, pneumonia, malaria, and measles</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>2004</YR>
<VL>80</VL>
<PG>193-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Corbin-2013" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Corbin 2013" TYPE="OTHER">
<AU>Corbin V, Beytout J, Auclair C, Chambon M, Mouly D, Chamoux A, et al</AU>
<TI>Shift of the 2009-2011 measles outbreak from children to adults: an observational review at the University Hospital of Clermont-Ferrand, France</TI>
<SO>Infection</SO>
<YR>2013 Jun 14 [Epub ahead of print]</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Curtale-2010" MODIFIED="2011-04-14 14:59:50 +1000" MODIFIED_BY="[Empty name]" NAME="Curtale 2010" TYPE="JOURNAL_ARTICLE">
<AU>Curtale F, Perrelli F, Mantovani J, Ciofi degli Atti M, Filia A, Nicoletti L, et al</AU>
<TI>Description of two measles outbreaks in the Lazio Region, Italy (2006-2007). Importance of pockets of low vaccine coverage in sustaining the infection</TI>
<SO>BMC Infectious Diseases</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Serres-2013" MODIFIED="2013-06-28 13:33:02 +1000" MODIFIED_BY="[Empty name]" NAME="De Serres 2013" TYPE="JOURNAL_ARTICLE">
<AU>De Serres G, Markowski F, Toth E, Landry M, Auger D, Mercier M, et al</AU>
<TI>Largest measles epidemic in North America in a decade--Quebec, Canada, 2011: contribution of susceptibility, serendipity, and superspreading events</TI>
<SO>Journal of Infectious Disease</SO>
<YR>2013</YR>
<VL>207</VL>
<PG>990-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deivanayagam-1994" MODIFIED="2008-03-13 11:00:43 +1000" MODIFIED_BY="Liz Dooley" NAME="Deivanayagam 1994" TYPE="JOURNAL_ARTICLE">
<AU>Deivanayagam N, Mala N, Ahamed SS, Shankar VJ</AU>
<TI>Measles associated diarrhea and pneumonia in south India</TI>
<SO>Indian Pediatrics</SO>
<YR>1994</YR>
<VL>31</VL>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Delaporte-2013" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Delaporte 2013" TYPE="JOURNAL_ARTICLE">
<AU>Delaporte E, Wyler Lazarevic CA, Iten A, Sudre P</AU>
<TI>Large measles outbreak in Geneva, Switzerland, January to August 2011: descriptive epidemiology and demonstration of quarantine effectiveness</TI>
<SO>Euro Surveillance</SO>
<YR>2013</YR>
<VL>18</VL>
<NO>6</NO>
<PG>20395</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dickersin-1994" MODIFIED="2011-06-27 00:10:52 +1000" MODIFIED_BY="[Empty name]" NAME="Dickersin 1994" NOTES="&lt;p&gt;Dickersin 1994. Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ 1994; 309:1286-91&lt;/p&gt;" NOTES_MODIFIED="2011-06-27 00:10:52 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dickersin K, Scherer R, Lefebvre C</AU>
<TI>Identifying relevant studies for systematic reviews</TI>
<SO>BMJ</SO>
<YR>1994</YR>
<VL>309</VL>
<PG>1286-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dover-1975" MODIFIED="2011-06-27 00:11:00 +1000" MODIFIED_BY="[Empty name]" NAME="Dover 1975" NOTES="&lt;p&gt;Dover AS, Escobar JA, Duenas AL, Leal EC. Pneumonia associated with measles. JAMA. 1975; 234(6): 612-4.&lt;/p&gt;" NOTES_MODIFIED="2011-06-27 00:11:00 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Dover AS, Escobar JA, Duenas AL, Leal EC</AU>
<TI>Pneumonia associated with measles</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>234</VL>
<NO>6</NO>
<PG>612-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ellison-1931" NAME="Ellison 1931" NOTES="&lt;p&gt;Ellison JB. Pneumonia in measles. Arch Dis Child 1931; 6: 37-51.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Ellison JB</AU>
<TI>Pneumonia in measles</TI>
<SO>Archives of Disease in Childhood</SO>
<YR>1931</YR>
<VL>6</VL>
<PG>37-51</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gadomski-1993" NAME="Gadomski 1993" NOTES="&lt;p&gt;Gadomski AM. Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections. Pediatr Infect Dis J 1993; 12: 115-20.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gadomski AM</AU>
<TI>Potential interventions for preventing pneumonia among young children: lack of effect of antibiotic treatment for upper respiratory infections</TI>
<SO>Pediatric Infectious Disease Journal</SO>
<YR>1993</YR>
<VL>12</VL>
<PG>115-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ghebrehewet-2013" MODIFIED="2013-06-28 14:12:44 +1000" MODIFIED_BY="[Empty name]" NAME="Ghebrehewet 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ghebrehewet S, Hayhurst G, Keenan A, Moore H</AU>
<TI>Outbreak of measles in Central and Eastern Cheshire, UK, October 2008-February 2009</TI>
<SO>Epidemiology and Infection</SO>
<YR>2012</YR>
<VL>9</VL>
<PG>1-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gremillion-1981" NAME="Gremillion 1981" NOTES="&lt;p&gt;Gremillion DH, Crawford GE. Measles pneumonia in young adults. An analysis of 106 cases. Am-J-Med 1981; 71(4): 539-42.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Gremillion DH, Crawford GE</AU>
<TI>Measles pneumonia in young adults. An analysis of 106 cases</TI>
<SO>American Journal of Medicine</SO>
<YR>1981</YR>
<VL>71</VL>
<NO>4</NO>
<PG>539-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grout-2013" MODIFIED="2013-06-28 14:13:16 +1000" MODIFIED_BY="[Empty name]" NAME="Grout 2013" TYPE="JOURNAL_ARTICLE">
<AU>Grout L, Minetti A, Hurtado N, François G, Fermon F, Chatelain A, et al</AU>
<TI>Measles in Democratic Republic of Congo: an outbreak description from Katanga, 2010--2011</TI>
<SO>BMC Infectious Disease</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>232</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2011-06-27 00:11:54 +1000" MODIFIED_BY="[Empty name]" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Altman DG, Sterne JAC (editors)</AU>
<TI>Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kaschula-1983" NAME="Kaschula 1983" NOTES="&lt;p&gt;Kaschula RO, Druker J, Kipps A. Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor. Rev-Infect-Dis 1983; 5(3): 395-404.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Kaschula RO, Druker J, Kipps A</AU>
<TI>Late morphologic consequences of measles: a lethal and debilitating lung disease among the poor</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1983</YR>
<VL>5</VL>
<NO>3</NO>
<PG>395-404</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kouadio-2010" MODIFIED="2011-04-14 15:03:53 +1000" MODIFIED_BY="[Empty name]" NAME="Kouadio 2010" TYPE="JOURNAL_ARTICLE">
<AU>Kouadio IK, Kamigaki T, Oshitani H</AU>
<TI>Measles outbreaks in displaced populations: a review of transmission, morbidity and mortality associated factors</TI>
<SO>BMC International Health Human Rights</SO>
<YR>2010</YR>
<VL>10</VL>
<PG>5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-le-Roux-2012" MODIFIED="2013-06-28 13:35:21 +1000" MODIFIED_BY="[Empty name]" NAME="le Roux 2012" TYPE="JOURNAL_ARTICLE">
<AU>le Roux DM, le Roux SM, Nuttall JJ, Eley BS</AU>
<TI>South African measles outbreak 2009 - 2010 as experienced by a paediatric hospital</TI>
<SO>South African Medical Journal</SO>
<YR>2012</YR>
<VL>102</VL>
<NO>9</NO>
<PG>760-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2013-06-28 14:20:10 +1000" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2011" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. Available from www.cochrane-handbook.org</SO>
<YR>2011</YR>
<ED>Higgins JPT, Green S</ED>
<PB>Wiley-Blackwell</PB>
<CY>Chichester</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mishra-2009" MODIFIED="2011-04-14 15:05:06 +1000" MODIFIED_BY="[Empty name]" NAME="Mishra 2009" TYPE="JOURNAL_ARTICLE">
<AU>Mishra A, Mishra S, Lahariya C, Jain P, Bhadoriya RS, Shrivastav D, et al</AU>
<TI>Practical observations from an epidemiological investigation of a measles outbreak in a district of India</TI>
<SO>Indian Journal of Community Medicine</SO>
<YR>2009</YR>
<VL>34</VL>
<NO>2</NO>
<PG>117-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mishra-2012" MODIFIED="2013-08-09 21:23:41 +1000" MODIFIED_BY="[Empty name]" NAME="Mishra 2012" TYPE="JOURNAL_ARTICLE">
<AU>Mishra PP, Chauhan NT</AU>
<TI>Double outbreak of measles in the talaja block of bhavnagar district, gujarat, India 2011: a need for improving the vaccine coverage and the community participation</TI>
<SO>Journal of Clinical and Diagnostic Research</SO>
<YR>2012</YR>
<VL>6</VL>
<PG>1713-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Morton-1986" NAME="Morton 1986" NOTES="&lt;p&gt;Morton R, Mee J. Measles Pneumonia: lung puncture findings in 56 cases related to chest X-ray changes and clinical features. Ann Trop Paediatr 1986; 6: 41-5.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Morton R, Mee J</AU>
<TI>Measles pneumonia: lung puncture findings in 56 cases related to chest X-ray changes and clinical features</TI>
<SO>Annals of Tropical Paediatrics</SO>
<YR>1986</YR>
<VL>6</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Muscat-2009" MODIFIED="2011-04-14 15:26:47 +1000" MODIFIED_BY="[Empty name]" NAME="Muscat 2009" TYPE="JOURNAL_ARTICLE">
<AU>Muscat M, Bang H, Wohlfahrt J, Glismann S, Mølbak K; EUVAC.NET Group</AU>
<TI>Measles in Europe: an epidemiological assessment</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<PG>383-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nmor-2011" MODIFIED="2011-04-19 14:58:05 +1000" MODIFIED_BY="[Empty name]" NAME="Nmor 2011" TYPE="JOURNAL_ARTICLE">
<AU>Nmor JC, Thanh HT, Goto K</AU>
<TI>Recurring measles epidemic in Vietnam 2005-2009: implication for strengthened control strategies</TI>
<SO>International Journal of Biological Sciences</SO>
<YR>2011</YR>
<VL>7</VL>
<NO>2</NO>
<PG>138-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ntshoe-2013" MODIFIED="2013-06-28 13:36:01 +1000" MODIFIED_BY="[Empty name]" NAME="Ntshoe 2013" TYPE="JOURNAL_ARTICLE">
<AU>Ntshoe GM, McAnerney JM, Archer BN, Smit SB, Harris BN, Tempia S, et al</AU>
<TI>Measles outbreak in South Africa: epidemiology of laboratory-confirmed measles cases and assessment of intervention, 2009-2011</TI>
<SO>PLoS One</SO>
<YR>2013</YR>
<VL>8</VL>
<NO>2</NO>
<PG>e55682</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Olson-1975" MODIFIED="2011-06-27 00:11:43 +1000" MODIFIED_BY="[Empty name]" NAME="Olson 1975" NOTES="&lt;p&gt;Olson RW, Hodges GR. Measles pneumonia. Bacterial suprainfection as a complicating factor. JAMA. 1975; 232(4): 363-5.&lt;/p&gt;" NOTES_MODIFIED="2011-06-27 00:11:43 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Olson RW, Hodges GR</AU>
<TI>Measles pneumonia. Bacterial suprainfection as a complicating factor</TI>
<SO>JAMA</SO>
<YR>1975</YR>
<VL>232</VL>
<NO>4</NO>
<PG>363-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perry-2004" MODIFIED="2008-03-13 11:03:04 +1000" MODIFIED_BY="Liz Dooley" NAME="Perry 2004" TYPE="JOURNAL_ARTICLE">
<AU>Perry RT, Halsey NA</AU>
<TI>The clinical significance of measles: a review</TI>
<SO>Journal of Infectious Diseases</SO>
<YR>2004</YR>
<VL>89</VL>
<NO>Suppl</NO>
<PG>4-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pezzotti-2013" MODIFIED="2013-06-28 14:13:52 +1000" MODIFIED_BY="[Empty name]" NAME="Pezzotti 2013" TYPE="JOURNAL_ARTICLE">
<AU>Pezzotti P, Valle S, Perrelli F, Guerra MP, Pozzato S, Chini F, et al</AU>
<TI>Measles outbreak in the Lazio region of Italy: surveillance and impact on Emergency Departments and hospitalizations</TI>
<SO>Annali di Lgiene</SO>
<YR>2013</YR>
<VL>25</VL>
<PG>299-309</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reddy-1986" MODIFIED="2011-04-18 10:59:34 +1000" MODIFIED_BY="[Empty name]" NAME="Reddy 1986" NOTES="&lt;p&gt;Reddy V, Bhaskaram P, Raghuramulu N, et al. Relation between measles, malnutrition and blindness; a prospective study in Indian children. Am J. Clin Nutr 1986; 44: 925-30.&lt;/p&gt;" NOTES_MODIFIED="2011-04-18 10:59:34 +1000" NOTES_MODIFIED_BY="[Empty name]" TYPE="JOURNAL_ARTICLE">
<AU>Reddy V, Bhaskaram P, Raghuramulu N, Milton RC, Rao V, Madhusudan J, et al</AU>
<TI>Relation between measles, malnutrition and blindness; a prospective study in Indian children</TI>
<SO>American Journal of Clinical Nutrition</SO>
<YR>1986</YR>
<VL>44</VL>
<PG>925-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2013-06-28 13:38:35 +1000" MODIFIED_BY="[Empty name]" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tricou-2013" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NAME="Tricou 2013" TYPE="JOURNAL_ARTICLE">
<AU>Tricou V, Pagonendji M, Manengu C, Mutombo J, Mabo RO, Gouandjika-Vasilache I</AU>
<TI>Measles outbreak in Northern Central African Republic 3 years after the last national immunization campaign</TI>
<SO>BMC Infectious Disease</SO>
<YR>2013</YR>
<VL>13</VL>
<PG>103</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wesley-1971" NAME="Wesley 1971" NOTES="&lt;p&gt;Wesley AG, Sutton JB, Widrich AJ. The aetiology of pneumonia associated with measles in Bantu children. S-Afr-Med-J 1971; 45(48): 1402-4.&lt;/p&gt;" TYPE="JOURNAL_ARTICLE">
<AU>Wesley AG, Sutton JB, Widrich AJ</AU>
<TI>The aetiology of pneumonia associated with measles in Bantu children</TI>
<SO>South African Medical Journal</SO>
<YR>1971</YR>
<VL>45</VL>
<NO>48</NO>
<PG>1402-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-1995" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="Liz Dooley" NAME="WHO 1995" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>Clinical research on treatment of measles: report of a meeting (WHO/CDR/95.15)</SO>
<YR>1995</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wolfson-2009" MODIFIED="2011-04-14 15:27:58 +1000" MODIFIED_BY="[Empty name]" NAME="Wolfson 2009" TYPE="JOURNAL_ARTICLE">
<AU>Wolfson LJ, Grais RF, Luquero FJ, Birmingham ME, Strebel PM</AU>
<TI>Estimates of measles case fatality ratios: a comprehensive review of community-based studies</TI>
<SO>International Journal of Epidemiology </SO>
<YR>2009</YR>
<VL>38</VL>
<PG>192-205</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yang-2011" MODIFIED="2011-06-28 13:08:15 +1000" MODIFIED_BY="[Empty name]" NAME="Yang 2011" TYPE="COCHRANE_REVIEW">
<AU>Yang HM, Mao M, Wan C</AU>
<TI>Vitamin A for treating measles in children</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>7</NO>
<IDENTIFIERS MODIFIED="2011-04-14 15:02:32 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-14 15:02:32 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001479.pub3"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2013-06-28 13:39:47 +1000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Kabra-2008" MODIFIED="2011-04-14 15:28:47 +1000" MODIFIED_BY="[Empty name]" NAME="Kabra 2008" TYPE="COCHRANE_REVIEW">
<AU>Kabra SK, Lodha R, Hilton DJ</AU>
<TI>Antibiotics for preventing complications in children with measles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2008</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2011-04-14 15:28:47 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2011-04-14 15:28:47 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001477.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Kabra-2011" MODIFIED="2013-06-28 13:39:47 +1000" MODIFIED_BY="[Empty name]" NAME="Kabra 2011" TYPE="COCHRANE_REVIEW">
<AU>Kabra SK, Lodha R, Hilton DJ</AU>
<TI>Antibiotics for preventing complications in children with measles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2011</YR>
<NO>9</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858.CD001477.pub3"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shann-1997" MODIFIED="2011-06-27 00:12:10 +1000" MODIFIED_BY="[Empty name]" NAME="Shann 1997" TYPE="JOURNAL_ARTICLE">
<AU>Shann F</AU>
<TI>Meta-analysis of trials of prophylactic antibiotics for children with measles: inadequate evidence</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>314</VL>
<PG>334-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shann-1999" MODIFIED="2008-03-03 12:22:38 +1000" MODIFIED_BY="[Empty name]" NAME="Shann 1999" TYPE="COCHRANE_REVIEW">
<AU>Shann F, D'Souza RM, D'Souza R</AU>
<TI>Antibiotics for preventing pneumonia in children with measles</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>2</NO>
<IDENTIFIERS MODIFIED="2008-03-03 12:22:38 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-03 12:22:38 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001477.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Shann-2000" MODIFIED="2008-03-03 12:24:01 +1000" MODIFIED_BY="[Empty name]" NAME="Shann 2000" TYPE="COCHRANE_REVIEW">
<AU>Antibiotics for preventing pneumonia in children with measles</AU>
<TI>Shann F, D'Souza RM, D'Souza R</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2008-03-03 12:24:01 +1000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-03-03 12:24:01 +1000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001477.pub2"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES MODIFIED="2008-03-13 18:14:47 +1000" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anderson-1939">
<CHAR_METHODS MODIFIED="2011-05-23 12:41:24 +1000" MODIFIED_BY="[Empty name]">
<P>Alternate participants were allocated to control or treatment groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>125 children with measles admitted to a hospital in Glasgow. 86% were under 6 years. Control group: 62 + 1 (withdrawn - measles not confirmed). Intervention group: 63. However, 13 participants in the control group and 16 participants in the intervention group already had pneumonia or empyema at the time of enrolment, therefore participants available for analysis of primary outcome (pneumonia) in the 2 groups were 49 and 47 patients respectively<BR/>
<BR/>On admission participants were:<BR/>- given diphtheria antitoxin 4000 units<BR/>- assessed for complications</P>
<P>Appearance of rash was considered first day of illness<BR/>
<BR/>Evaluation done by 1 person</P>
<P>Evenly balanced by age, sex and duration of illness before admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-27 00:06:29 +1000" MODIFIED_BY="[Empty name]">
<P>The treatment group was given sulphanilamide 0.25 g to those under 5 and 0.5 g to those over 5</P>
<P>Children under 5 years were given 0.25 g 4-hourly for 10 days, followed by 0.25 g 3 times a day until discharge<BR/>Children over 5 years were given 0.5 g hourly for 10 days, followed by 0.25 g 3 times a day until discharge<BR/>All participants received the same nursing and general care<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-20 11:11:52 +1000" MODIFIED_BY="[Empty name]">
<P>The duration in days of primary pyrexia<BR/>The duration in days until clinical cure of complications noted on admission<BR/>The incidence and nature of complications arising in hospital<BR/>The duration in days of clinical complications arising in hospital<BR/>The duration in days of residence in hospital. There were more complications in the sulphanilamide group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>1 control withdrawn (measles not confirmed)<BR/>Conclusion: sulphanilamide decreases duration of bronchopneumonia, but has no effect on other complications</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garly-2006">
<CHAR_METHODS MODIFIED="2011-05-23 12:37:47 +1000" MODIFIED_BY="[Empty name]">
<P>Randomised, double-blind, placebo-controlled trial</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-05-11 10:01:55 +1000" MODIFIED_BY="Liz Dooley">
<P>84 children (age range 0.49 to 24.8 years) with measles. Separate data for children below 18 years (81 children) were obtained from trial authors</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-11 10:02:16 +1000" MODIFIED_BY="Liz Dooley">
<P>The treatment group received co-trimoxazole. Children below 5 years of age and weighing &lt; 18 kg received paediatric cotrimoxazole tablets 3 times a day and those above 5 years or &gt; 18 kg received adult cotrimoxazole tablets twice a day. Control group received a placebo twice a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-27 00:06:44 +1000" MODIFIED_BY="[Empty name]">
<P>Treatment failure due to pneumonia, admission to hospital or both. Other morbidities</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>2 participants in the treatment group and 1 patient in the control group received the wrong dose of the trial drug. A total of 87 participants were enrolled in the study. Follow-up of 1 and 2 participants, respectively, was not available in the treatment and control groups and these participants were not included in the intention-to-treat analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-27 00:07:05 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gibel-1942">
<CHAR_METHODS MODIFIED="2011-06-27 00:06:55 +1000" MODIFIED_BY="[Empty name]">
<P>Participants were divided into 2 groups on admission</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-27 00:07:00 +1000" MODIFIED_BY="[Empty name]">
<P>401 children with measles admitted to King's Avenue Hospital, New York from December 1940 to June 1941. Separate data for those who already had pneumonia were not mentioned in the paper. However, data on uncomplicated cases (we presume children without pneumonia) in intervention and control groups at time of enrolment were 82 and 148 respectively. All aged under 6 years<BR/>
<BR/>Control group: 201 participants<BR/>Treatment group: 153 participants<BR/>
<BR/>Duration of illness similar at the time of admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-02-26 14:16:28 +1000" MODIFIED_BY="[Empty name]">
<P>The treatment group received sulfathiazole according to body weight<BR/>Dose 215 mg/kg for the first 24 hours, then 143 mg/kg daily until discharge<BR/>Controls were treated symptomatically<BR/>Otherwise the participants received the same nursing care and were admitted to the same ward</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-26 14:16:34 +1000" MODIFIED_BY="[Empty name]">
<P>Duration in days of primary pyrexia<BR/>Duration in days until clinical cure of complications noted on admission<BR/>Incidence and nature of complications arising in hospital<BR/>Duration in days of clinical complications arising in hospital<BR/>Duration in days of residence in hospital<BR/>Death rate of measles complicated by bronchopneumonia as compared to previous years<BR/>A comparison of the death rate in this hospital in previous years and the death rate this year with sulfathiazole</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-06-27 00:07:05 +1000" MODIFIED_BY="[Empty name]">
<P>One case of bronchopneumonia and 1 case of otitis media were excluded</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2011-06-27 00:07:59 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hogarth-1939">
<CHAR_METHODS MODIFIED="2011-05-23 12:40:15 +1000" MODIFIED_BY="[Empty name]">
<P>Alternate participants were assigned to treatment and control groups</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-27 00:07:54 +1000" MODIFIED_BY="[Empty name]">
<P>329 children admitted to a hospital with measles from December 1937 to July 1938<BR/>74% were under 4 years of age. No withdrawals<BR/>
<BR/>158 received proseptasine<BR/>
<BR/>Cases were graded into mild, moderate and severe on admission<BR/>The participants were stratified in the 2 groups by degree of severity (toxemia, intensity of rash, condition of the mouth)<BR/>Prophylactic dose of diphtheria antitoxin given at the time of admission<BR/>The control group had more younger children<BR/>These differences were considered slight and did not preclude comparison<BR/>
<BR/>All participants assessed by 1 person at the time of admission</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-27 00:07:59 +1000" MODIFIED_BY="[Empty name]">
<P>The treatment group received para-benzylaminobenzenesulphonamide (proseptasine) for a period of 10 days after admission to hospital:<BR/>&lt; 1 year, 0.5 g 3 times a day for 5 days, then 0.5 g twice a day for 5 days<BR/>1 to 5 years, 1 g 3 times a day for 5 days, then 0.5 g 3 times a day for 5 days<BR/>&gt; 5 years, 1 g 4 times a day for 5 days, then 0.5 g 4 times a day for 5 days</P>
<P>Duration of treatment 10 days</P>
<P>Controls received no antibiotic or placebo but got the same nursing care</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-02-19 13:48:13 +1000" MODIFIED_BY="[Empty name]">
<P>Complications observed for 12 days after admission</P>
<P>Bronchopneumonia - clinical or X-ray<BR/>Acute otitis media<BR/>Cervical adenitis<BR/>Enteritis<BR/>Other complications (tonsillitis, conjunctivitis, boils, styes)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-05-11 10:05:36 +1000" MODIFIED_BY="Liz Dooley">
<P>Conclusion: proseptasine is of value in reducing the incidence of complications such as bronchopneumonia, acute otitis media and cervical adenitis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-14 08:39:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karelitz-1951">
<CHAR_METHODS MODIFIED="2011-06-28 12:58:18 +1000" MODIFIED_BY="[Empty name]">
<P>First 15 participants were given chlortetracycline, then subsequent participants were treated with chlortetracycline or penicillin or remained untreated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2011-06-28 12:58:29 +1000" MODIFIED_BY="[Empty name]">
<P>Children all aged under 9 years admitted from 15 February to 15 May 1950 to the Willard Parker Hospital, New York<BR/>
<BR/>Chlortetracycline: 45 participants<BR/>Penicillin: 44 participants<BR/>No therapy: 43<BR/>
<BR/>Onset of illness: appearance of rash<BR/>All seen by trial author soon after admission<BR/>Seen daily for severity and complications<BR/>Chest X-ray done in 35 cases assigned penicillin or chlortetracycline groups</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-06-28 12:58:41 +1000" MODIFIED_BY="[Empty name]">
<P>Chlortetracycline, procaine penicillin</P>
<P>First 15 cases were treated with chlortetracycline, later alternate cases were given chlortetracycline or penicillin or left untreated</P>
<P>Dose: chlortetracycline: oral 60 mg/kg 4 times a day<BR/>Penicillin: IM 300,000 units</P>
<P>3/4 of the chlortetracycline treated participants started therapy in the pre-eruptive period or at the beginning of the rash<BR/>3/5 of the penicillin treated participants were given their first dose of penicillin at the beginning of the rash<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2013-08-14 08:39:19 +1000" MODIFIED_BY="[Empty name]">
<P>Duration and intensity of the rash, temperature, rhinorrhea, photophobia, cough and complications<BR/>Pneumonia<BR/>Death<BR/>
</P>
<P>None of the participants developed complications in the chlortetracycline group, 1 in the penicillin group and 10 in the untreated group</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-14 08:39:19 +1000" MODIFIED_BY="[Empty name]">
<P>Conclusion: very few of the untreated control cases were observed by the trial authors. Information was obtained from hospital records. There were problems with ascertaining duration of cough, photophobia and rhinorrhea<BR/>The main difference was in the complications that developed in the untreated group and the prolonged course in these cases<BR/>Children receiving chlortetracycline or penicillin had reduced fever duration<BR/>Neither chlortetracycline nor penicillin given to children with pre-eruptive rubeola or begun on the first day of rash seem to have had any definite therapeutic effect on the course of the primary disease<BR/>Temperature from appearance of rash lasted 2.2, 2.8 and 4.4 days in the chlortetracycline, penicillin and control groups, respectively<BR/>An earlier drop in temperature in the treated cases was statistically significant<BR/>Chlortetracycline and penicillin were effective against otitis media and pneumonia present on admission, and for the complications which developed during the course of the disease<BR/>Chlortetracycline and penicillin are useful in the prevention and cure of secondary infection in measles</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-13 23:36:58 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karelitz-1954">
<CHAR_METHODS MODIFIED="2011-06-27 00:09:16 +1000" MODIFIED_BY="[Empty name]">
<P>Consecutive inpatients; children with complications were alternated into the 2 penicillin groups while children without complications were left untreated</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-13 23:36:58 +1000" MODIFIED_BY="[Empty name]">
<P>Children with measles admitted to William Parker Hospital, New York<BR/>98% aged &lt; 10 years</P>
<P>Benzethacil: 61 participants<BR/>Procaine penicillin: 67 participants<BR/>No treatment : 41 participants</P>
<P>Additional 87 participants were observed in April and May 1953</P>
<P>Ages of the 2 groups were well-balanced</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2013-08-13 23:36:58 +1000" MODIFIED_BY="Liz Dooley">
<P>Aqueous benzethacil 600,000 units single injection in children under 5 years<BR/>Aqueous procaine penicillin 300,000 units on admission and daily for a total of 4 doses<BR/>Aqueous procaine penicillin 600,000 units on admission and repeated on the third and sixth days<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-05-11 10:11:02 +1000" MODIFIED_BY="Liz Dooley">
<P>Pneumonia - diagnosed clinically and also confirmed by X-ray</P>
<P>Discharged within 2 to 3 days. Could not observe late complications<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2013-08-13 23:36:58 +1000" MODIFIED_BY="Liz Dooley">
<P>Fever in treatment groups was of a shorter duration<BR/>No complications observed in the group receiving 4 doses of aqueous penicillin<BR/>2 children developed bacterial complications in the benzathine penicillin group<BR/>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Prasad-1967">
<CHAR_METHODS MODIFIED="2011-06-15 07:30:33 +1000" MODIFIED_BY="Liz Dooley">
<P>Participants were given placebo or tetracycline. Patient allocation not clear<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]">
<P>Inpatients and outpatients at SN Medical College, Agra, India<BR/>
<BR/>90% &lt; 5 years<BR/>27 cases &gt; 5 years of age</P>
<P>158 children were randomized:<BR/>- 78 to tetracycline<BR/>- 80 to placebo</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2011-05-11 10:11:36 +1000" MODIFIED_BY="Liz Dooley">
<P>Tetracycline 33 mg/kg for 7 days or placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2011-06-27 00:10:01 +1000" MODIFIED_BY="[Empty name]">
<P>Complications<BR/>Clinical improvement, i.e. temperature, cough and general condition</P>
<P>216 cases had an X-ray examination. 16 were Mantoux-positive and showed radiological changes - hilar gland enlargement, infiltration, increased lung marking. These participants were excluded from the study</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2011-05-11 10:11:58 +1000" MODIFIED_BY="Liz Dooley">
<P>Radiological changes were 50% less with tetracycline and serious complications like bronchopneumonia and lobar type were completely absent</P>
<P>Use of tetracycline reduces the incidence of serious complications like consolidation and lung collapse and perhaps subsequent sequelae like bronchiectasis and pulmonary fibrosis<BR/>81 cases were followed for 6 to 7 months</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>IM: intramuscular<BR/>RCT: randomized controlled trial</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2011-06-27 00:10:23 +1000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2011-06-27 00:10:19 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Samb-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-27 00:10:19 +1000" MODIFIED_BY="[Empty name]">
<P>Cohort study comparing the development of respiratory symptoms and case-fatality rates with historical controls. Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2011-06-27 00:10:23 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Thompson-1938">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2011-06-27 00:10:23 +1000" MODIFIED_BY="[Empty name]">
<P>Children hospitalised with severe measles treated with sulphonamide or benzyl sulphonamide were compared to children with a milder form of measles (who did not receive antibiotics) for development of bronchopneumonia, otitis media, laryngitis, rhinitis and skin infections. Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2008-02-19 14:38:51 +1000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Weinstein-1955">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2008-02-19 14:38:51 +1000" MODIFIED_BY="[Empty name]">
<P>Children with measles without obvious secondary infections. Compared children who received antibiotics prescribed by their primary care physicians and those who did not receive antibiotics for development of pneumonia, otitis media, laryngitis and laryngotracheobronchitis. Not a controlled trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2013-06-20 01:55:59 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-27 00:06:36 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>Alternate participants were allocated to 2 groups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:39:34 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>Not clear from paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-18 12:13:25 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Not mentioned in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-23 12:40:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Alternate participants received intervention or no treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-28 12:59:12 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>First 15 participants were given chlortetracycline, then subsequent participants were treated with chlortetracycline or penicillin or remained untreated</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:55:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:55:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>Not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-23 12:39:14 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>Alternate participants received study drug with supportive care or only supportive care</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-23 12:37:40 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>Double-blind RCT</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-27 00:07:13 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Participants who had pneumonia were not allocated to the no antibiotics group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-15 07:30:07 +1000" MODIFIED_BY="Liz Dooley" RESULT="NO" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Alternate participants were assigned to intervention and control group</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:10:25 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>No details about allocation concealment mentioned in the paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-05-11 10:11:23 +1000" MODIFIED_BY="Liz Dooley" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Not used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>Double-blind randomized trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-12" LEVEL="GROUP" MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="Liz Dooley" NO="12">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-12.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-06-20 01:38:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>Double-blind randomized controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-12.01" MODIFIED="2011-06-15 07:31:01 +1000" MODIFIED_BY="Liz Dooley" RESULT="YES" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>Double-blind</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-13" LEVEL="GROUP" MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" NO="13">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-13.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-06-20 01:38:50 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>No blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-14 08:39:17 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>Double-blind randomized controlled trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Open-label trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Open-label</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-13.01" MODIFIED="2013-08-14 08:39:21 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>Double-blind randomized trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2011-05-23 12:37:05 +1000" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-23 12:39:16 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>Details of all the participants not mentioned in the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-20 01:39:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>All data shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-06-27 00:07:21 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Participants who had pneumonia and other complications were allocated to intervention and control groups. Outcome of those who did not have pneumonia at time of enrolment are not very clearly mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2011-05-23 12:40:19 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Details of all the enrolled participants available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-20 01:54:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>Not clear from data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-06-20 01:55:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Not clear from paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>All enrolled participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:38:50 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>Not clear from paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:39:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>Details of all the enrolled participants are not very clear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:40:46 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>Not clear from data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:54:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>Not clear from data</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:55:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Not clear from paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>All enrolled participants accounted for</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2013-06-20 01:55:59 +1000" MODIFIED_BY="[Empty name]" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-04-18 12:12:55 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anderson-1939">
<DESCRIPTION>
<P>No details about supporting agency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:39:34 +1000" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garly-2006">
<DESCRIPTION>
<P>None</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-27 00:07:22 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gibel-1942">
<DESCRIPTION>
<P>No mention of supporting agency</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2011-06-27 00:08:23 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hogarth-1939">
<DESCRIPTION>
<P>No mention of financial support</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:54:54 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1951">
<DESCRIPTION>
<P>Not clear from paper</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:55:28 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Karelitz-1954">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2013-06-20 01:55:59 +1000" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Prasad-1967">
<DESCRIPTION>
<P>Funding not mentioned</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2011-03-22 19:25:47 +1000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2013-08-13 23:29:21 +1000" MODIFIED_BY="[Empty name]">
<COMPARISON ID="CMP-001" MODIFIED="2013-08-13 23:28:08 +1000" MODIFIED_BY="[Empty name]" NO="1">
<NAME>Antibiotic versus placebo or no antibiotic (excluding children with pneumonia or sepsis on admission)</NAME>
<DICH_OUTCOME CHI2="16.20255651729547" CI_END="1.0108107143814107" CI_START="0.11873631304348269" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3464389374918725" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="59" I2="62.96880684480082" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.004669836702627959" LOG_CI_START="-0.9254164407538253" LOG_EFFECT_SIZE="-0.4603733020255987" METHOD="MH" MODIFIED="2013-08-13 23:28:08 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.012707095740209118" P_Q="1.0" P_Z="0.052345359761719015" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="EFFECT_SIZE" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.1672504821346559" TOTALS="YES" TOTAL_1="654" TOTAL_2="609" WEIGHT="99.99999999999999" Z="1.940282559337514">
<NAME>Development of pneumonia (7 studies)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="601" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="13.140247590859536"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" MODIFIED="2011-03-15 18:57:56 +1000" MODIFIED_BY="[Empty name]" ORDER="600" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="8.555432228653142"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 18:30:53 +1000" MODIFIED_BY="[Empty name]" ORDER="603" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="12.49713437966375"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 18:28:48 +1000" MODIFIED_BY="[Empty name]" ORDER="602" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="22.686298435141612"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="599" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="15.879529783743827"/>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-11 22:42:25 +1000" MODIFIED_BY="[Empty name]" ORDER="597" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="18.30711230531826"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-04-14 15:29:29 +1000" MODIFIED_BY="[Empty name]" ORDER="598" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="8.934245276619864"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9933294697755173" CI_END="1.2221782080061783" CI_START="0.2300453566401327" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5302418521189926" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="25" I2="24.874718635008012" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.087134535784527" LOG_CI_START="-0.6381865283453692" LOG_EFFECT_SIZE="-0.27552599628042107" METHOD="MH" MODIFIED="2013-08-13 22:35:24 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="0.2621854052941571" P_Q="1.0" P_Z="0.13647321227774478" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.1835206745412738" TOTALS="YES" TOTAL_1="428" TOTAL_2="338" WEIGHT="100.0" Z="1.4890537617626147">
<NAME>Development of diarrhoea</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.088234210245716" CI_START="0.11376202336409214" EFFECT_SIZE="0.35185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03672237447137971" LOG_CI_START="-0.9440026922116588" LOG_EFFECT_SIZE="-0.45364015887013953" ORDER="615" O_E="0.0" SE="0.5760827588369919" STUDY_ID="STD-Anderson-1939" TOTAL_1="50" TOTAL_2="50" VAR="0.33187134502923976" WEIGHT="35.22070903138233"/>
<DICH_DATA CI_END="1.673420634044366" CI_START="0.055502971999114165" EFFECT_SIZE="0.3047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2236051197329725" LOG_CI_START="-1.2556837612330367" LOG_EFFECT_SIZE="-0.516039320750032" ORDER="612" O_E="0.0" SE="0.8689416112774919" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.7550595238095239" WEIGHT="19.34035300370252"/>
<DICH_DATA CI_END="3.4842571894204335" CI_START="0.4368124452048059" EFFECT_SIZE="1.2336802270577105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5421102048383796" LOG_CI_START="-0.35970499666142935" LOG_EFFECT_SIZE="0.09120260408847514" ORDER="614" O_E="0.0" SE="0.5297307134182306" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.2806146287385876" WEIGHT="39.11030303041632"/>
<DICH_DATA CI_END="3.7941845429987873" CI_START="0.006161359637754676" EFFECT_SIZE="0.15289648622981955" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5791184504474591" LOG_CI_START="-2.210323440754733" LOG_EFFECT_SIZE="-0.8156024951536368" ORDER="613" O_E="0.0" SE="1.638531974852221" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="2.6847870326131194" WEIGHT="6.32863493449884"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.14331154508421E-31" CI_END="1.0039529853028573" CI_START="0.15318148085558567" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3921568627450981" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" I2="100.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.0017133754567909645" LOG_CI_START="-0.8147937363247012" LOG_EFFECT_SIZE="-0.4065401804339551" METHOD="MH" MODIFIED="2013-08-13 22:35:28 +1000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.0" P_Q="1.0" P_Z="0.05096927981166801" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="132" TOTAL_2="80" WEIGHT="100.0" Z="1.9517383263948898">
<NAME>Development of conjunctivitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.003952985302857" CI_START="0.15318148085558567" EFFECT_SIZE="0.39215686274509803" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="17" LOG_CI_END="0.0017133754567908684" LOG_CI_START="-0.8147937363247012" LOG_EFFECT_SIZE="-0.4065401804339552" ORDER="616" O_E="0.0" SE="0.4796203192358367" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.23003565062388592" WEIGHT="100.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="617" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1951" TOTAL_1="88" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6831826539911856" CI_END="0.7306598532980906" CI_START="0.1621146332084618" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3441666080804012" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="-0.1362847546639532" LOG_CI_START="-0.7901777819753117" LOG_EFFECT_SIZE="-0.4632312683196324" METHOD="MH" MODIFIED="2013-08-13 22:35:31 +1000" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.6406792067239163" P_Q="1.0" P_Z="0.0054870338091678105" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="544" TOTAL_2="489" WEIGHT="100.0" Z="2.776957589385565">
<NAME>Development of otitis media</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5914599596297836" CI_START="0.09605228236254622" EFFECT_SIZE="0.39097744360902253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20179571645335248" LOG_CI_START="-1.017492311117926" LOG_EFFECT_SIZE="-0.40784829733228667" ORDER="621" O_E="0.0" SE="0.7162158229684459" STUDY_ID="STD-Anderson-1939" TOTAL_1="60" TOTAL_2="59" VAR="0.5129651050703682" WEIGHT="28.760788864612238"/>
<DICH_DATA CI_END="4.676612955571102" CI_START="0.035416672682088195" EFFECT_SIZE="0.4069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6699314284470355" LOG_CI_START="-1.4507922422336195" LOG_EFFECT_SIZE="-0.39043040689329206" ORDER="618" O_E="0.0" SE="1.2457235819092922" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="1.5518272425249169" WEIGHT="9.507038333621473"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="622" O_E="0.0" SE="0.0" STUDY_ID="STD-Gibel-1942" TOTAL_1="195" TOTAL_2="180" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.242083560438021" CI_START="0.147129390236779" EFFECT_SIZE="0.4274891774891775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.09415081372817963" LOG_CI_START="-0.8323005649154727" LOG_EFFECT_SIZE="-0.3690748755936465" ORDER="620" O_E="0.0" SE="0.5442021258235679" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.29615595375089043" WEIGHT="49.81591926479423"/>
<DICH_DATA CI_END="0.7916234849253174" CI_START="0.010098820739981303" EFFECT_SIZE="0.08941176470588236" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.10148133015262915" LOG_CI_START="-1.9957293367143734" LOG_EFFECT_SIZE="-1.0486053334335013" ORDER="619" O_E="0.0" SE="1.1126906557332263" STUDY_ID="STD-Karelitz-1951" TOTAL_1="86" TOTAL_2="43" VAR="1.2380804953560371" WEIGHT="11.916253536972055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="4.058328725423113" CI_START="0.006459100211184767" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.16190476190476188" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.05" LOG_CI_END="0.6083472220603685" LOG_CI_START="-2.189827977443697" LOG_EFFECT_SIZE="-0.7907403776916642" METHOD="MH" MODIFIED="2013-08-13 22:35:34 +1000" MODIFIED_BY="[Empty name]" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.26797495078475897" Q="0.0" RANDOM="YES" SCALE="758.2368826239217" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="87" TOTAL_2="43" WEIGHT="100.0" Z="1.1077381156633397">
<NAME>Development of croup</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.058328725423113" CI_START="0.006459100211184767" EFFECT_SIZE="0.1619047619047619" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6083472220603685" LOG_CI_START="-2.189827977443697" LOG_EFFECT_SIZE="-0.7907403776916642" ORDER="623" O_E="0.0" SE="1.6436619633793148" STUDY_ID="STD-Karelitz-1951" TOTAL_1="87" TOTAL_2="43" VAR="2.701624649859944" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.2973815593983159" CI_END="0.7193360806903513" CI_START="0.00985821921466827" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.08421028899407594" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="-0.14306815567066558" LOG_CI_START="-2.0062015287799695" LOG_EFFECT_SIZE="-1.0746348422253176" METHOD="MH" MODIFIED="2013-08-13 22:35:37 +1000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.5855287092437755" P_Q="1.0" P_Z="0.02376103134224904" Q="0.0" RANDOM="YES" SCALE="424.17780315043393" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="151" TOTAL_2="105" WEIGHT="100.0" Z="2.260971348259929">
<NAME>Development of tonsillitis</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favors treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favors control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.8949243859322321" CI_START="0.0028481402336447527" EFFECT_SIZE="0.05048633626679018" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="8" LOG_CI_END="-0.048213657599904446" LOG_CI_START="-2.54543863118731" LOG_EFFECT_SIZE="-1.296826144393607" ORDER="625" O_E="0.0" SE="1.4668823109482243" STUDY_ID="STD-Anderson-1939" TOTAL_1="63" TOTAL_2="62" VAR="2.1517437141728033" WEIGHT="55.66376159819969"/>
<DICH_DATA CI_END="4.012162977467327" CI_START="0.006386607742468238" EFFECT_SIZE="0.160075329566855" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6033785661173583" LOG_CI_START="-2.194729756851711" LOG_EFFECT_SIZE="-0.7956755953671764" ORDER="624" O_E="0.0" SE="1.6436226797716138" STUDY_ID="STD-Karelitz-1951" TOTAL_1="88" TOTAL_2="43" VAR="2.701495513459621" WEIGHT="44.3362384018003"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.0625041594685694E-5" CI_END="19.630048231121265" CI_START="0.4717960899360812" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="3.043251550677285" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="1.2929213666649113" LOG_CI_START="-0.32624566270057276" LOG_EFFECT_SIZE="0.4833378519821693" METHOD="MH" MODIFIED="2013-08-13 22:35:37 +1000" MODIFIED_BY="Liz Dooley" NO="7" P_CHI2="0.9973992140409023" P_Q="1.0" P_Z="0.2419452860849276" Q="0.0" RANDOM="YES" SCALE="407.56" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="808" TOTAL_2="674" WEIGHT="100.0" Z="1.1701384292900767">
<NAME>Death</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.15042500904634" CI_START="0.3085362809051242" EFFECT_SIZE="3.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4792934384590106" LOG_CI_START="-0.5106937597654387" LOG_EFFECT_SIZE="0.48429983934678583" ORDER="604" O_E="0.0" SE="1.168928330832541" STUDY_ID="STD-Anderson-1939" TOTAL_1="63" TOTAL_2="62" VAR="1.366393442622951" WEIGHT="66.2037726422085"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="610" O_E="0.0" SE="0.0" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.82678829550863" CI_START="0.12270145296750727" EFFECT_SIZE="3.030075187969925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.874057104898674" LOG_CI_START="-0.9111502945506266" LOG_EFFECT_SIZE="0.4814534051740237" ORDER="605" O_E="0.0" SE="1.6360446134355002" STUDY_ID="STD-Gibel-1942" TOTAL_1="200" TOTAL_2="201" VAR="2.676641977151315" WEIGHT="33.7962273577915"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="606" O_E="0.0" SE="0.0" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="607" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="608" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="609" O_E="0.0" SE="0.0" STUDY_ID="STD-Prasad-1967" TOTAL_1="78" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2011-05-11 09:49:22 +1000" MODIFIED_BY="Liz Dooley" NO="2">
<NAME>Baseline characteristics of participants</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.0" ESTIMABLE="NO" I2="0.0" I2_Q="0.0" ID="CMP-002.01" MODIFIED="2011-05-11 09:48:39 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="NaN" TOTALS="YES" TOTAL_1="46" TOTAL_2="38" UNITS="" WEIGHT="0.0" Z="0.0">
<NAME>Median age</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" MEAN_1="4.4" MEAN_2="5.9" ORDER="626" SD_1="0.0" SD_2="0.0" SE="0.0" STUDY_ID="STD-Garly-2006" TOTAL_1="46" TOTAL_2="38" WEIGHT="0.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="3.8230542024612277" CI_END="1.9105397578897079" CI_START="0.6917296568052369" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="1.1495986304088084" ESTIMABLE="YES" EVENTS_1="181" EVENTS_2="160" I2="47.68580579599346" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.2811560796860103" LOG_CI_START="-0.16006360423925864" LOG_EFFECT_SIZE="0.06054623772337584" METHOD="MH" MODIFIED="2011-05-11 09:48:51 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="0.14785455033144368" P_Q="1.0" P_Z="0.5906385442524723" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.09785144828823053" TOTALS="YES" TOTAL_1="307" TOTAL_2="300" WEIGHT="100.00000000000001" Z="0.537910930362374">
<NAME>Male sex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.6946720673283835" CI_START="0.6597380806861388" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="30" LOG_CI_END="0.4305059205374703" LOG_CI_START="-0.18062844732087044" LOG_EFFECT_SIZE="0.12493873660829993" ORDER="628" O_E="0.0" SE="0.35898335284389943" STUDY_ID="STD-Anderson-1939" TOTAL_1="63" TOTAL_2="62" VAR="0.1288690476190476" WEIGHT="29.627443564882714"/>
<DICH_DATA CI_END="1.3527959136227046" CI_START="0.2283237212576633" EFFECT_SIZE="0.555765595463138" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="23" LOG_CI_END="0.13123228272260168" LOG_CI_START="-0.6414489659686586" LOG_EFFECT_SIZE="-0.2551083416230285" ORDER="627" O_E="0.0" SE="0.45387679031511347" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.20600414078674947" WEIGHT="22.106385200759195"/>
<DICH_DATA CI_END="2.1807903149460293" CI_START="0.983041248615349" EFFECT_SIZE="1.4641744548286604" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="107" LOG_CI_END="0.3386139097603909" LOG_CI_START="-0.0074282586987001594" LOG_EFFECT_SIZE="0.16559282553084537" ORDER="629" O_E="0.0" SE="0.20326688268922985" STUDY_ID="STD-Gibel-1942" TOTAL_1="200" TOTAL_2="201" VAR="0.04131742559819713" WEIGHT="48.266171234358104"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="7.713046949923103" CI_START="0.9677893367304284" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.7321428571428577" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-002.03" LOG_CI_END="0.8872259749552199" LOG_CI_START="-0.014219167332423215" LOG_EFFECT_SIZE="0.43650340381139846" METHOD="MH" MODIFIED="2011-05-11 09:49:00 +1000" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.057678691278680604" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="41" TOTAL_2="34" WEIGHT="100.0" Z="1.898132033699489">
<NAME>Weight for age z-score &lt; -2</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.713046949923103" CI_START="0.9677893367304284" EFFECT_SIZE="2.732142857142857" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.8872259749552199" LOG_CI_START="-0.014219167332423215" LOG_EFFECT_SIZE="0.4365034038113984" ORDER="630" O_E="0.0" SE="0.5295133388051818" STUDY_ID="STD-Garly-2006" TOTAL_1="41" TOTAL_2="34" VAR="0.28038437597261123" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.1046606516236865" CI_END="1.916098435504812" CI_START="1.1772897329574024" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="1.501933092869172" ESTIMABLE="YES" EVENTS_1="284" EVENTS_2="171" I2="0.0" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="0.2824178162761629" LOG_CI_START="0.07088335659019755" LOG_EFFECT_SIZE="0.1766505864331803" METHOD="MH" MODIFIED="2011-05-11 09:49:11 +1000" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.7165163684856426" P_Q="1.0" P_Z="0.0010622524223917564" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="697" TOTAL_2="546" WEIGHT="100.00000000000001" Z="3.2734977343257365">
<NAME>Children below age of two years</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.0813838749746063" CI_START="0.5119462702532876" EFFECT_SIZE="1.032258064516129" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="31" LOG_CI_END="0.3183521856457688" LOG_CI_START="-0.29077561667450214" LOG_EFFECT_SIZE="0.013788284485633285" ORDER="634" O_E="0.0" SE="0.35780468631417767" STUDY_ID="STD-Anderson-1939" TOTAL_1="63" TOTAL_2="62" VAR="0.1280241935483871" WEIGHT="12.059947196529082"/>
<DICH_DATA CI_END="2.546410953187396" CI_START="1.0451480309427008" EFFECT_SIZE="1.6313725490196078" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="45" LOG_CI_END="0.4059284937006841" LOG_CI_START="0.01917780668489104" LOG_EFFECT_SIZE="0.21255315019278756" ORDER="635" O_E="0.0" SE="0.2271792679998534" STUDY_ID="STD-Gibel-1942" TOTAL_1="200" TOTAL_2="201" VAR="0.051610419808949225" WEIGHT="29.91576158045598"/>
<DICH_DATA CI_END="2.1912487007142736" CI_START="0.9046207936010162" EFFECT_SIZE="1.4079236977256053" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="58" LOG_CI_END="0.34069167159002534" LOG_CI_START="-0.04353343378842933" LOG_EFFECT_SIZE="0.148579118900798" ORDER="633" O_E="0.0" SE="0.2256957288442501" STUDY_ID="STD-Hogarth-1939" TOTAL_1="170" TOTAL_2="159" VAR="0.05093856201853726" WEIGHT="30.310337647731338"/>
<DICH_DATA CI_END="5.3897220143863915" CI_START="0.918180858514866" EFFECT_SIZE="2.2245762711864407" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="8" LOG_CI_END="0.7315663661642213" LOG_CI_START="-0.03707176529252066" LOG_EFFECT_SIZE="0.34724730043585034" ORDER="631" O_E="0.0" SE="0.4515018432378043" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="0.2038539144471348" WEIGHT="7.57387964935136"/>
<DICH_DATA CI_END="2.7202893032253694" CI_START="0.9188770514531617" EFFECT_SIZE="1.5810159436410827" ESTIMABLE="YES" EVENTS_1="82" EVENTS_2="29" LOG_CI_END="0.43461509378165153" LOG_CI_START="-0.03674259465040227" LOG_EFFECT_SIZE="0.19893624956562464" ORDER="632" O_E="0.0" SE="0.27687783944317645" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="0.07666133797472141" WEIGHT="20.140073925932263"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6843805120065511" CI_END="1.8537556586442414" CI_START="0.8131327992790782" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="1.2277416372726075" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="0.268052489735275" LOG_CI_START="-0.08983852047697082" LOG_EFFECT_SIZE="0.08910698462915204" METHOD="MH" MODIFIED="2011-05-11 09:49:22 +1000" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.6404120113444873" P_Q="1.0" P_Z="0.3290764745616921" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="529" TOTAL_2="385" WEIGHT="100.00000000000001" Z="0.9759757896155531">
<NAME>Age less than one year</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.2395376783386185" CI_START="0.6816781024888845" EFFECT_SIZE="1.7" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.627318499353643" LOG_CI_START="-0.16642065659709512" LOG_EFFECT_SIZE="0.2304489213782739" MODIFIED="2011-03-15 21:52:11 +1000" MODIFIED_BY="[Empty name]" ORDER="126" O_E="0.0" SE="0.4662463092776528" STUDY_ID="STD-Anderson-1939" TOTAL_1="65" TOTAL_2="60" VAR="0.21738562091503266" WEIGHT="20.330402137719208"/>
<DICH_DATA CI_END="2.8804606009692417" CI_START="0.6825197995784326" EFFECT_SIZE="1.4021310181531177" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="14" LOG_CI_END="0.4594619393095786" LOG_CI_START="-0.1658847454257678" LOG_EFFECT_SIZE="0.14678859694190544" MODIFIED="2011-03-15 21:58:11 +1000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.36733173812955583" STUDY_ID="STD-Gibel-1942" TOTAL_1="200" TOTAL_2="201" VAR="0.1349326058372806" WEIGHT="32.75366294704228"/>
<DICH_DATA CI_END="5.848092801324844" CI_START="0.3847408166112341" EFFECT_SIZE="1.5" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.7670142556706511" LOG_CI_START="-0.4148317375592886" LOG_EFFECT_SIZE="0.17609125905568124" MODIFIED="2011-03-15 22:00:29 +1000" MODIFIED_BY="[Empty name]" ORDER="128" O_E="0.0" SE="0.6942221866552843" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="0.48194444444444445" WEIGHT="9.1702210557795"/>
<DICH_DATA CI_END="1.7102385238996756" CI_START="0.44722746510525246" EFFECT_SIZE="0.8745659722222222" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.2330566848888594" LOG_CI_START="-0.3494715334369518" LOG_EFFECT_SIZE="-0.05820742427404619" MODIFIED="2011-03-15 22:05:17 +1000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.3421799590057677" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="0.11708712434518886" WEIGHT="37.74571385945902"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2013-08-13 23:29:21 +1000" MODIFIED_BY="Liz Dooley" NO="3">
<NAME>Sensitivity analysis</NAME>
<DICH_OUTCOME CHI2="16.23458467707494" CI_END="1.5180853996581432" CI_START="0.07449949965857464" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3362983834536214" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="32" I2="69.20155273783774" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.18129620341523342" LOG_CI_START="-1.1278466439798922" LOG_EFFECT_SIZE="-0.4732752202823294" METHOD="MH" MODIFIED="2013-08-13 23:28:36 +1000" MODIFIED_BY="Liz Dooley" NO="1" P_CHI2="0.006205301686516673" P_Q="1.0" P_Z="0.15644957410529514" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="EFFECT_SIZE" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="2.341077309249543" TOTALS="YES" TOTAL_1="577" TOTAL_2="529" WEIGHT="100.00000000000001" Z="1.4171140886181035">
<NAME>Development of pneumonia (without Prasad 1967)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="641" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="17.16387331368857"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" ORDER="640" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="12.682821798369545"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:02:08 +1000" MODIFIED_BY="[Empty name]" ORDER="638" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="16.60064296030102"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="639" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="19.366462979291722"/>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:02:08 +1000" MODIFIED_BY="[Empty name]" ORDER="636" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="21.08781981799787"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:02:08 +1000" MODIFIED_BY="[Empty name]" ORDER="637" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="13.098379130351287"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.8449010376805" CI_END="1.257665871210376" CI_START="0.13099976843973696" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.40589892572304165" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="56" I2="66.3184012658043" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.09956527579615936" LOG_CI_START="-0.8827294720192995" LOG_EFFECT_SIZE="-0.3915820981115701" METHOD="MH" MODIFIED="2013-08-13 23:28:42 +1000" MODIFIED_BY="Liz Dooley" NO="2" P_CHI2="0.011046034268566984" P_Q="1.0" P_Z="0.11813716160750695" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.2034165307945315" TOTALS="YES" TOTAL_1="565" TOTAL_2="566" WEIGHT="100.0" Z="1.5626405638351089">
<NAME>Development of pneumonia (without Karelitz 1951)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:07:48 +1000" MODIFIED_BY="[Empty name]" ORDER="648" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="19.976933268020737"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:07:48 +1000" MODIFIED_BY="[Empty name]" ORDER="649" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="13.731586448040037"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:07:48 +1000" MODIFIED_BY="[Empty name]" ORDER="650" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="9.858684464197141"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="651" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="17.377933203863254"/>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="652" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="14.427151209616415"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:08:00 +1000" MODIFIED_BY="[Empty name]" ORDER="653" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="24.62771140626242"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.37655492529931" CI_END="1.3583760118904527" CI_START="0.16990848621133225" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4804160820435693" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="47" I2="56.049963870161214" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="0.13302000358627752" LOG_CI_START="-0.7697849294139775" LOG_EFFECT_SIZE="-0.31838246291385" METHOD="MH" MODIFIED="2013-08-13 23:28:49 +1000" MODIFIED_BY="Liz Dooley" NO="3" P_CHI2="0.044404631413429985" P_Q="1.0" P_Z="0.1668493301857305" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8402721332731238" TOTALS="YES" TOTAL_1="498" TOTAL_2="528" WEIGHT="100.0" Z="1.3823986507174506">
<NAME>Development of pneumonia (without Karelitz 1954)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:03:48 +1000" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="21.575880692257577"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:03:48 +1000" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="13.642418879438239"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:03:48 +1000" MODIFIED_BY="[Empty name]" ORDER="644" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="9.331054516746102"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="645" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="18.112353762214408"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" ORDER="646" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="8.894502385815064"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:04:05 +1000" MODIFIED_BY="[Empty name]" ORDER="647" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="28.443789763528606"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="16.197377615949367" CI_END="1.2157628233199547" CI_START="0.09174391833939824" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.33397431814848005" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="54" I2="69.13080550103025" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="0.0848488590074169" LOG_CI_START="-1.0374227152958317" LOG_EFFECT_SIZE="-0.4762869281442074" METHOD="MH" MODIFIED="2013-08-13 23:28:58 +1000" MODIFIED_BY="Liz Dooley" NO="4" P_CHI2="0.00630259279816614" P_Q="1.0" P_Z="0.09619248813940501" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.5997916177006901" TOTALS="YES" TOTAL_1="495" TOTAL_2="439" WEIGHT="100.00000000000001" Z="1.6635995187696364">
<NAME>Development of pneumonia (without Hogarth 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:00:08 +1000" MODIFIED_BY="[Empty name]" ORDER="654" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="21.065813546366588"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:00:08 +1000" MODIFIED_BY="[Empty name]" ORDER="655" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="15.405420986960959"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:00:08 +1000" MODIFIED_BY="[Empty name]" ORDER="656" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="11.516838008358967"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" MODIFIED="2011-03-15 19:12:34 +1000" MODIFIED_BY="[Empty name]" ORDER="657" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="11.082385641558627"/>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" MODIFIED="2011-03-15 19:12:34 +1000" MODIFIED_BY="[Empty name]" ORDER="658" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="16.071385168092693"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:12:34 +1000" MODIFIED_BY="[Empty name]" ORDER="659" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="24.858156648662177"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.967255316453096" CI_END="0.5989084145002164" CI_START="0.1171381486826581" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.2648679348373853" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="59" I2="37.243130772092215" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.22263958515366006" LOG_CI_START="-0.9313016440886579" LOG_EFFECT_SIZE="-0.5769706146211588" METHOD="MH" MODIFIED="2013-08-13 23:29:09 +1000" MODIFIED_BY="Liz Dooley" NO="5" P_CHI2="0.15804961552733954" P_Q="1.0" P_Z="0.0014154420819829983" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.36437332158730495" TOTALS="YES" TOTAL_1="572" TOTAL_2="461" WEIGHT="100.0" Z="3.1914834737868687">
<NAME>Development of pneumonia (without Gibel 1942)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:13:12 +1000" MODIFIED_BY="[Empty name]" ORDER="660" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="20.93912243156214"/>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:13:12 +1000" MODIFIED_BY="[Empty name]" ORDER="661" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="10.928857800958005"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="662" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="16.092264700358932"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" ORDER="663" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="6.451419699070589"/>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="664" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="11.798721654214251"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:13:25 +1000" MODIFIED_BY="[Empty name]" ORDER="665" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="33.78961371383609"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.137677912242657" CI_END="1.3220819526913166" CI_START="0.12224255757228297" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4020132823889586" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="53" I2="66.96983494439243" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="0.12125837685799819" LOG_CI_START="-0.9127775723162421" LOG_EFFECT_SIZE="-0.39575959772912195" METHOD="MH" MODIFIED="2013-08-13 23:29:15 +1000" MODIFIED_BY="Liz Dooley" NO="6" P_CHI2="0.009789996855646521" P_Q="1.0" P_Z="0.13354047004471922" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.3174918945292369" TOTALS="YES" TOTAL_1="610" TOTAL_2="571" WEIGHT="100.0" Z="1.500285475963532">
<NAME>Development of pneumonia (without Garly 2006)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.530537090681869" CI_START="0.17563245608254893" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.4032127072486056" LOG_CI_START="-0.7553952253599681" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2011-03-15 19:06:33 +1000" MODIFIED_BY="[Empty name]" ORDER="666" O_E="0.0" SE="0.6805720348160387" STUDY_ID="STD-Anderson-1939" TOTAL_1="47" TOTAL_2="49" VAR="0.4631782945736434" WEIGHT="20.718723340713478"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:06:22 +1000" MODIFIED_BY="[Empty name]" ORDER="667" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="10.567657344359269"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="668" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="18.17469554476764"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" ORDER="669" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="10.138086292112067"/>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="670" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="15.233989680338162"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:06:22 +1000" MODIFIED_BY="[Empty name]" ORDER="671" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="25.166847797709373"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="15.457005183674005" CI_END="1.14022344406138" CI_START="0.07954291719264645" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="0.30115892646921244" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="53" I2="67.65220726404945" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.05698996626100753" LOG_CI_START="-1.0993984855472108" LOG_EFFECT_SIZE="-0.5212042596431017" METHOD="MH" MODIFIED="2013-08-13 23:29:21 +1000" MODIFIED_BY="Liz Dooley" NO="7" P_CHI2="0.008578126769301586" P_Q="1.0" P_Z="0.07726520024052695" Q="0.0" RANDOM="YES" SCALE="2.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.692808770220082" TOTALS="YES" TOTAL_1="607" TOTAL_2="560" WEIGHT="100.00000000000001" Z="1.7667792788694512">
<NAME>Development of pneumonia (without Anderson 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0818443452745865" CI_START="0.014219874560657536" EFFECT_SIZE="0.12403100775193798" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.03416477939235587" LOG_CI_START="-1.8471042346790043" LOG_EFFECT_SIZE="-0.9064697276433242" MODIFIED="2011-03-15 19:13:58 +1000" MODIFIED_BY="[Empty name]" ORDER="672" O_E="0.0" SE="1.1050667312973255" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="38" VAR="1.2211724806201552" WEIGHT="15.83419331708451"/>
<DICH_DATA CI_END="453.90110389404055" CI_START="1.4029929950397575" EFFECT_SIZE="25.235294117647058" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.6569612389545862" LOG_CI_START="0.14705550265831432" LOG_EFFECT_SIZE="1.4020083708064504" MODIFIED="2011-03-15 19:13:58 +1000" MODIFIED_BY="[Empty name]" ORDER="673" O_E="0.0" SE="1.4743310537342003" STUDY_ID="STD-Gibel-1942" TOTAL_1="82" TOTAL_2="148" VAR="2.1736520560049972" WEIGHT="11.933534185890663"/>
<DICH_DATA CI_END="2.1983953745573293" CI_START="0.0803864342165543" EFFECT_SIZE="0.42038216560509556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.34210580162111326" LOG_CI_START="-1.0948172353558434" LOG_EFFECT_SIZE="-0.376355716867365" ORDER="674" O_E="0.0" SE="0.8440557048040126" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.7124300328121984" WEIGHT="19.183351935780657"/>
<DICH_DATA CI_END="1.280815557243615" CI_START="0.003262731243606222" EFFECT_SIZE="0.06464485235434957" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.10748659403930585" LOG_CI_START="-2.486418698270306" LOG_EFFECT_SIZE="-1.1894660521155003" ORDER="675" O_E="0.0" SE="1.5236728087409446" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="2.321578828096519" WEIGHT="11.493793590711741"/>
<DICH_DATA CI_END="0.2909497839133644" CI_START="0.004729924996187306" EFFECT_SIZE="0.037096774193548385" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="12" LOG_CI_END="-0.5361819610183219" LOG_CI_START="-2.3251457459430003" LOG_EFFECT_SIZE="-1.430663853480661" ORDER="676" O_E="0.0" SE="1.050846182778311" STUDY_ID="STD-Karelitz-1954" TOTAL_1="156" TOTAL_2="81" VAR="1.1042776998597474" WEIGHT="16.495929940573912"/>
<DICH_DATA CI_END="0.848476987182544" CI_START="0.1873746781460845" EFFECT_SIZE="0.39872685185185186" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="27" LOG_CI_END="-0.07135993233884362" LOG_CI_START="-0.7272891001316536" LOG_EFFECT_SIZE="-0.39932451623524867" MODIFIED="2011-03-15 19:13:58 +1000" MODIFIED_BY="[Empty name]" ORDER="677" O_E="0.0" SE="0.3852960400632426" STUDY_ID="STD-Prasad-1967" TOTAL_1="77" TOTAL_2="80" VAR="0.14845303848841584" WEIGHT="25.059197029958526"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="30.15042500904634" CI_START="0.3085362809051242" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="1.4792934384590106" LOG_CI_START="-0.5106937597654387" LOG_EFFECT_SIZE="0.48429983934678583" METHOD="MH" MODIFIED="2011-05-11 09:50:55 +1000" MODIFIED_BY="Liz Dooley" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.3400905987855346" Q="0.0" RANDOM="YES" SCALE="144.17" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="511" TOTAL_2="510" WEIGHT="99.99999999999999" Z="0.9539862806003576">
<NAME>Death (without Gibel 1942)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="30.15042500904634" CI_START="0.3085362809051242" EFFECT_SIZE="3.05" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.4792934384590106" LOG_CI_START="-0.5106937597654387" LOG_EFFECT_SIZE="0.48429983934678583" ORDER="678" O_E="0.0" SE="1.168928330832541" STUDY_ID="STD-Anderson-1939" TOTAL_1="63" TOTAL_2="62" VAR="1.366393442622951" WEIGHT="99.99999999999999"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="679" O_E="0.0" SE="0.0" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="680" O_E="0.0" SE="0.0" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="681" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="81" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="682" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1954" TOTAL_1="78" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="683" O_E="0.0" SE="0.0" STUDY_ID="STD-Prasad-1967" TOTAL_1="78" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.11109601203381367" CI_END="19.937714706530826" CI_START="0.21318805779920097" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="2.0616698754261975" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.09" LOG_CI_END="1.299675377284491" LOG_CI_START="-0.6712371269305067" LOG_EFFECT_SIZE="0.3142191251769921" METHOD="MH" MODIFIED="2011-05-11 09:51:06 +1000" MODIFIED_BY="Liz Dooley" NO="9" P_CHI2="0.7388998163909133" P_Q="1.0" P_Z="0.5320056873050485" Q="0.0" RANDOM="YES" SCALE="77.67" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="745" TOTAL_2="612" WEIGHT="100.0" Z="0.6249472437599456">
<NAME>Death (without Anderson 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="684" O_E="0.0" SE="0.0" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="74.82678829550863" CI_START="0.12270145296750727" EFFECT_SIZE="3.030075187969925" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.874057104898674" LOG_CI_START="-0.9111502945506266" LOG_EFFECT_SIZE="0.4814534051740237" ORDER="685" O_E="0.0" SE="1.6360446134355002" STUDY_ID="STD-Gibel-1942" TOTAL_1="200" TOTAL_2="201" VAR="2.676641977151315" WEIGHT="50.07484447203058"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="686" O_E="0.0" SE="0.0" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="687" O_E="0.0" SE="0.0" STUDY_ID="STD-Karelitz-1951" TOTAL_1="89" TOTAL_2="43" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="34.76748437830592" CI_START="0.05646685452737421" EFFECT_SIZE="1.4011461318051577" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5411732681884547" LOG_CI_START="-1.2482064038595742" LOG_EFFECT_SIZE="0.14648343216444037" ORDER="688" O_E="0.0" SE="1.6384954270130756" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="2.684667264342761" WEIGHT="49.925155527969416"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="689" O_E="0.0" SE="0.0" STUDY_ID="STD-Prasad-1967" TOTAL_1="78" TOTAL_2="80" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3198547233163094" CI_END="1.4380508181003793" CI_START="0.22503463149707653" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5688683818997926" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="24" I2="39.756400002885194" I2_Q="0.0" ID="CMP-003.10" LOG_CI_END="0.15777423349513484" LOG_CI_START="-0.6477506413965624" LOG_EFFECT_SIZE="-0.24498820395071375" METHOD="MH" MODIFIED="2011-05-11 09:51:21 +1000" MODIFIED_BY="Liz Dooley" NO="10" P_CHI2="0.1901529908327072" P_Q="1.0" P_Z="0.23318803444212766" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.26810801974465415" TOTALS="YES" TOTAL_1="253" TOTAL_2="257" WEIGHT="99.99999999999999" Z="1.1921867873915402">
<NAME>Diarrhoea (without Karelitz 1954)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.088234210245716" CI_START="0.11376202336409214" EFFECT_SIZE="0.35185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03672237447137971" LOG_CI_START="-0.9440026922116588" LOG_EFFECT_SIZE="-0.45364015887013953" ORDER="690" O_E="0.0" SE="0.5760827588369919" STUDY_ID="STD-Anderson-1939" TOTAL_1="50" TOTAL_2="50" VAR="0.33187134502923976" WEIGHT="37.31614761924938"/>
<DICH_DATA CI_END="1.673420634044366" CI_START="0.055502971999114165" EFFECT_SIZE="0.3047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2236051197329725" LOG_CI_START="-1.2556837612330367" LOG_EFFECT_SIZE="-0.516039320750032" ORDER="691" O_E="0.0" SE="0.8689416112774919" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.7550595238095239" WEIGHT="21.881967118145372"/>
<DICH_DATA CI_END="3.4842571894204335" CI_START="0.4368124452048059" EFFECT_SIZE="1.2336802270577105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5421102048383796" LOG_CI_START="-0.35970499666142935" LOG_EFFECT_SIZE="0.09120260408847514" ORDER="692" O_E="0.0" SE="0.5297307134182306" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.2806146287385876" WEIGHT="40.80188526260524"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.23285637422606265" CI_END="0.7805487794753915" CI_START="0.12822747474114876" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.31636655781611184" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="18" I2="0.0" I2_Q="0.0" ID="CMP-003.11" LOG_CI_END="-0.10759995103202649" LOG_CI_START="-0.8920189104641688" LOG_EFFECT_SIZE="-0.4998094307480977" METHOD="MH" MODIFIED="2011-05-11 09:51:36 +1000" MODIFIED_BY="Liz Dooley" NO="11" P_CHI2="0.8900940180337417" P_Q="1.0" P_Z="0.012501373790051515" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="269" TOTAL_2="168" WEIGHT="100.0" Z="2.4976665125710307">
<NAME>Diarrhoea (without Hogarth 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.088234210245716" CI_START="0.11376202336409214" EFFECT_SIZE="0.35185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03672237447137971" LOG_CI_START="-0.9440026922116588" LOG_EFFECT_SIZE="-0.45364015887013953" ORDER="693" O_E="0.0" SE="0.5760827588369919" STUDY_ID="STD-Anderson-1939" TOTAL_1="50" TOTAL_2="50" VAR="0.33187134502923976" WEIGHT="63.973721095715"/>
<DICH_DATA CI_END="1.673420634044366" CI_START="0.055502971999114165" EFFECT_SIZE="0.3047619047619048" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.2236051197329725" LOG_CI_START="-1.2556837612330367" LOG_EFFECT_SIZE="-0.516039320750032" ORDER="694" O_E="0.0" SE="0.8689416112774919" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="0.7550595238095239" WEIGHT="28.118372389295583"/>
<DICH_DATA CI_END="3.7941845429987873" CI_START="0.006161359637754676" EFFECT_SIZE="0.15289648622981955" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5791184504474591" LOG_CI_START="-2.210323440754733" LOG_EFFECT_SIZE="-0.8156024951536368" ORDER="695" O_E="0.0" SE="1.638531974852221" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="2.6847870326131194" WEIGHT="7.907906514989416"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3809551919441363" CI_END="1.7092400345645056" CI_START="0.1986419052719821" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5826891941962216" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="40.84511960509159" I2_Q="0.0" ID="CMP-003.12" LOG_CI_END="0.23280305649879107" LOG_CI_START="-0.7019291279020418" LOG_EFFECT_SIZE="-0.2345630357016253" METHOD="MH" MODIFIED="2011-05-11 09:51:51 +1000" MODIFIED_BY="Liz Dooley" NO="12" P_CHI2="0.1844316599353647" P_Q="1.0" P_Z="0.32527665204798206" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3638522669568405" TOTALS="YES" TOTAL_1="384" TOTAL_2="301" WEIGHT="100.0" Z="0.9836723496886131">
<NAME>Diarrhoea (without Garly 2006)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.088234210245716" CI_START="0.11376202336409214" EFFECT_SIZE="0.35185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03672237447137971" LOG_CI_START="-0.9440026922116588" LOG_EFFECT_SIZE="-0.45364015887013953" ORDER="696" O_E="0.0" SE="0.5760827588369919" STUDY_ID="STD-Anderson-1939" TOTAL_1="50" TOTAL_2="50" VAR="0.33187134502923976" WEIGHT="43.332411018799846"/>
<DICH_DATA CI_END="3.4842571894204335" CI_START="0.4368124452048059" EFFECT_SIZE="1.2336802270577105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5421102048383796" LOG_CI_START="-0.35970499666142935" LOG_EFFECT_SIZE="0.09120260408847514" ORDER="697" O_E="0.0" SE="0.5297307134182306" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.2806146287385876" WEIGHT="46.77878989817402"/>
<DICH_DATA CI_END="3.7941845429987873" CI_START="0.006161359637754676" EFFECT_SIZE="0.15289648622981955" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5791184504474591" LOG_CI_START="-2.210323440754733" LOG_EFFECT_SIZE="-0.8156024951536368" ORDER="698" O_E="0.0" SE="1.638531974852221" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="2.6847870326131194" WEIGHT="9.888799083026136"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.3809551919441363" CI_END="1.7092400345645054" CI_START="0.1986419052719821" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5826891941962214" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" I2="40.84511960509159" I2_Q="0.0" ID="CMP-003.13" LOG_CI_END="0.23280305649879102" LOG_CI_START="-0.7019291279020418" LOG_EFFECT_SIZE="-0.23456303570162537" METHOD="MH" MODIFIED="2011-05-11 09:52:08 +1000" MODIFIED_BY="Liz Dooley" NO="13" P_CHI2="0.1844316599353647" P_Q="1.0" P_Z="0.32527665204798195" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.3638522669568405" TOTALS="YES" TOTAL_1="384" TOTAL_2="301" WEIGHT="100.0" Z="0.9836723496886133">
<NAME>Diarrhoea (without Anderson 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.088234210245716" CI_START="0.11376202336409214" EFFECT_SIZE="0.35185185185185186" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.03672237447137971" LOG_CI_START="-0.9440026922116588" LOG_EFFECT_SIZE="-0.45364015887013953" ORDER="699" O_E="0.0" SE="0.5760827588369919" STUDY_ID="STD-Garly-2006" TOTAL_1="50" TOTAL_2="50" VAR="0.33187134502923976" WEIGHT="43.332411018799846"/>
<DICH_DATA CI_END="3.4842571894204335" CI_START="0.4368124452048059" EFFECT_SIZE="1.2336802270577105" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.5421102048383796" LOG_CI_START="-0.35970499666142935" LOG_EFFECT_SIZE="0.09120260408847514" ORDER="700" O_E="0.0" SE="0.5297307134182306" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.2806146287385876" WEIGHT="46.77878989817402"/>
<DICH_DATA CI_END="3.7941845429987873" CI_START="0.006161359637754676" EFFECT_SIZE="0.15289648622981955" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.5791184504474591" LOG_CI_START="-2.210323440754733" LOG_EFFECT_SIZE="-0.8156024951536368" ORDER="701" O_E="0.0" SE="1.638531974852221" STUDY_ID="STD-Karelitz-1954" TOTAL_1="175" TOTAL_2="81" VAR="2.6847870326131194" WEIGHT="9.888799083026136"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6632165065662536" CI_END="0.7461262262628786" CI_START="0.15325988156497786" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3381585679375471" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="24" I2="0.0" I2_Q="0.0" ID="CMP-003.14" LOG_CI_END="-0.12718769433412563" LOG_CI_START="-0.8145715143900363" LOG_EFFECT_SIZE="-0.47087960436208093" METHOD="MH" MODIFIED="2011-05-11 09:52:19 +1000" MODIFIED_BY="Liz Dooley" NO="14" P_CHI2="0.4353488209730707" P_Q="1.0" P_Z="0.007247029480627026" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="500" TOTAL_2="452" WEIGHT="99.99999999999999" Z="2.6852743363353553">
<NAME>Development of otitis media (without Garly 2006)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5914599596297836" CI_START="0.09605228236254622" EFFECT_SIZE="0.39097744360902253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20179571645335248" LOG_CI_START="-1.017492311117926" LOG_EFFECT_SIZE="-0.40784829733228667" ORDER="702" O_E="0.0" SE="0.7162158229684459" STUDY_ID="STD-Anderson-1939" TOTAL_1="60" TOTAL_2="59" VAR="0.5129651050703682" WEIGHT="31.78234896393929"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="705" O_E="0.0" SE="0.0" STUDY_ID="STD-Gibel-1942" TOTAL_1="195" TOTAL_2="180" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.242083560438021" CI_START="0.147129390236779" EFFECT_SIZE="0.4274891774891775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.09415081372817963" LOG_CI_START="-0.8323005649154727" LOG_EFFECT_SIZE="-0.3690748755936465" ORDER="703" O_E="0.0" SE="0.5442021258235679" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.29615595375089043" WEIGHT="55.049495946934705"/>
<DICH_DATA CI_END="0.7916234849253174" CI_START="0.010098820739981303" EFFECT_SIZE="0.08941176470588236" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.10148133015262915" LOG_CI_START="-1.9957293367143734" LOG_EFFECT_SIZE="-1.0486053334335013" ORDER="704" O_E="0.0" SE="1.1126906557332263" STUDY_ID="STD-Karelitz-1951" TOTAL_1="86" TOTAL_2="43" VAR="1.2380804953560371" WEIGHT="13.168155089125989"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.63971708208134" CI_END="0.7975750776773876" CI_START="0.1339822650169606" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.32689587857342994" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-003.15" LOG_CI_END="-0.09822842515313505" LOG_CI_START="-0.8729526845830391" LOG_EFFECT_SIZE="-0.4855905548680871" METHOD="MH" MODIFIED="2011-05-11 09:52:31 +1000" MODIFIED_BY="Liz Dooley" NO="15" P_CHI2="0.4404941830589696" P_Q="1.0" P_Z="0.01401115002582361" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="484" TOTAL_2="430" WEIGHT="100.0" Z="2.4569774011585186">
<NAME>Development of otitis media (without Anderson 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="4.676612955571102" CI_START="0.035416672682088195" EFFECT_SIZE="0.4069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6699314284470355" LOG_CI_START="-1.4507922422336195" LOG_EFFECT_SIZE="-0.39043040689329206" ORDER="706" O_E="0.0" SE="1.2457235819092922" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="1.5518272425249169" WEIGHT="13.34523246692564"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="707" O_E="0.0" SE="0.0" STUDY_ID="STD-Gibel-1942" TOTAL_1="195" TOTAL_2="180" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.242083560438021" CI_START="0.147129390236779" EFFECT_SIZE="0.4274891774891775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.09415081372817963" LOG_CI_START="-0.8323005649154727" LOG_EFFECT_SIZE="-0.3690748755936465" ORDER="708" O_E="0.0" SE="0.5442021258235679" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.29615595375089043" WEIGHT="69.92766830351438"/>
<DICH_DATA CI_END="0.7916234849253174" CI_START="0.010098820739981303" EFFECT_SIZE="0.08941176470588236" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.10148133015262915" LOG_CI_START="-1.9957293367143734" LOG_EFFECT_SIZE="-1.0486053334335013" ORDER="709" O_E="0.0" SE="1.1126906557332263" STUDY_ID="STD-Karelitz-1951" TOTAL_1="86" TOTAL_2="43" VAR="1.2380804953560371" WEIGHT="16.727099229559983"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6831826539911856" CI_END="0.7306598532980906" CI_START="0.1621146332084618" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3441666080804012" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-003.16" LOG_CI_END="-0.1362847546639532" LOG_CI_START="-0.7901777819753117" LOG_EFFECT_SIZE="-0.4632312683196324" METHOD="MH" MODIFIED="2011-05-11 09:52:45 +1000" MODIFIED_BY="Liz Dooley" NO="16" P_CHI2="0.6406792067239163" P_Q="1.0" P_Z="0.0054870338091678105" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="349" TOTAL_2="309" WEIGHT="100.0" Z="2.776957589385565">
<NAME>Development of otitis media (without Gibel 1942)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5914599596297836" CI_START="0.09605228236254622" EFFECT_SIZE="0.39097744360902253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20179571645335248" LOG_CI_START="-1.017492311117926" LOG_EFFECT_SIZE="-0.40784829733228667" ORDER="710" O_E="0.0" SE="0.7162158229684459" STUDY_ID="STD-Anderson-1939" TOTAL_1="60" TOTAL_2="59" VAR="0.5129651050703682" WEIGHT="28.760788864612238"/>
<DICH_DATA CI_END="4.676612955571102" CI_START="0.035416672682088195" EFFECT_SIZE="0.4069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6699314284470355" LOG_CI_START="-1.4507922422336195" LOG_EFFECT_SIZE="-0.39043040689329206" ORDER="711" O_E="0.0" SE="1.2457235819092922" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="1.5518272425249169" WEIGHT="9.507038333621473"/>
<DICH_DATA CI_END="1.242083560438021" CI_START="0.147129390236779" EFFECT_SIZE="0.4274891774891775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.09415081372817963" LOG_CI_START="-0.8323005649154727" LOG_EFFECT_SIZE="-0.3690748755936465" ORDER="712" O_E="0.0" SE="0.5442021258235679" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.29615595375089043" WEIGHT="49.81591926479423"/>
<DICH_DATA CI_END="0.7916234849253174" CI_START="0.010098820739981303" EFFECT_SIZE="0.08941176470588236" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.10148133015262915" LOG_CI_START="-1.9957293367143734" LOG_EFFECT_SIZE="-1.0486053334335013" ORDER="713" O_E="0.0" SE="1.1126906557332263" STUDY_ID="STD-Karelitz-1951" TOTAL_1="86" TOTAL_2="43" VAR="1.2380804953560371" WEIGHT="11.916253536972055"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010007924089103039" CI_END="0.921129004530125" CI_START="0.1851823502861228" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.4130094841230709" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-003.17" LOG_CI_END="-0.03567954240666839" LOG_CI_START="-0.7324004082513628" LOG_EFFECT_SIZE="-0.3840399753290156" METHOD="MH" MODIFIED="2011-05-11 09:53:00 +1000" MODIFIED_BY="Liz Dooley" NO="17" P_CHI2="0.9950085369427402" P_Q="1.0" P_Z="0.03071804767105777" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="458" TOTAL_2="446" WEIGHT="100.0" Z="2.1607061225472366">
<NAME>Development of otitis media (without Karelitz 1951)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5914599596297836" CI_START="0.09605228236254622" EFFECT_SIZE="0.39097744360902253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20179571645335248" LOG_CI_START="-1.017492311117926" LOG_EFFECT_SIZE="-0.40784829733228667" ORDER="714" O_E="0.0" SE="0.7162158229684459" STUDY_ID="STD-Anderson-1939" TOTAL_1="60" TOTAL_2="59" VAR="0.5129651050703682" WEIGHT="32.65164121587882"/>
<DICH_DATA CI_END="4.676612955571102" CI_START="0.035416672682088195" EFFECT_SIZE="0.4069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6699314284470355" LOG_CI_START="-1.4507922422336195" LOG_EFFECT_SIZE="-0.39043040689329206" ORDER="715" O_E="0.0" SE="1.2457235819092922" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="1.5518272425249169" WEIGHT="10.79318116607578"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="716" O_E="0.0" SE="0.0" STUDY_ID="STD-Gibel-1942" TOTAL_1="195" TOTAL_2="180" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.242083560438021" CI_START="0.147129390236779" EFFECT_SIZE="0.4274891774891775" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.09415081372817963" LOG_CI_START="-0.8323005649154727" LOG_EFFECT_SIZE="-0.3690748755936465" ORDER="717" O_E="0.0" SE="0.5442021258235679" STUDY_ID="STD-Hogarth-1939" TOTAL_1="159" TOTAL_2="170" VAR="0.29615595375089043" WEIGHT="56.55517761804539"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.3677684261747183" CI_END="0.8032051596185336" CI_START="0.09589140729733184" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="OR" EFFECT_SIZE="0.27752562603172204" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-003.18" LOG_CI_END="-0.0951735103750262" LOG_CI_START="-1.0182203076421374" LOG_EFFECT_SIZE="-0.5566969090085818" METHOD="MH" MODIFIED="2011-05-11 09:53:18 +1000" MODIFIED_BY="Liz Dooley" NO="18" P_CHI2="0.504653049587446" P_Q="1.0" P_Z="0.018071985585544223" Q="0.0" RANDOM="YES" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="385" TOTAL_2="319" WEIGHT="99.99999999999999" Z="2.3641399226822686">
<NAME>Development of otitis media (without Hogarth 1939)</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.5914599596297836" CI_START="0.09605228236254622" EFFECT_SIZE="0.39097744360902253" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.20179571645335248" LOG_CI_START="-1.017492311117926" LOG_EFFECT_SIZE="-0.40784829733228667" ORDER="718" O_E="0.0" SE="0.7162158229684459" STUDY_ID="STD-Anderson-1939" TOTAL_1="60" TOTAL_2="59" VAR="0.5129651050703682" WEIGHT="57.31058224692279"/>
<DICH_DATA CI_END="4.676612955571102" CI_START="0.035416672682088195" EFFECT_SIZE="0.4069767441860465" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.6699314284470355" LOG_CI_START="-1.4507922422336195" LOG_EFFECT_SIZE="-0.39043040689329206" ORDER="719" O_E="0.0" SE="1.2457235819092922" STUDY_ID="STD-Garly-2006" TOTAL_1="44" TOTAL_2="37" VAR="1.5518272425249169" WEIGHT="18.944330939895"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="720" O_E="0.0" SE="0.0" STUDY_ID="STD-Gibel-1942" TOTAL_1="195" TOTAL_2="180" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.7916234849253174" CI_START="0.010098820739981303" EFFECT_SIZE="0.08941176470588236" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="-0.10148133015262915" LOG_CI_START="-1.9957293367143734" LOG_EFFECT_SIZE="-1.0486053334335013" ORDER="721" O_E="0.0" SE="1.1126906557332263" STUDY_ID="STD-Karelitz-1951" TOTAL_1="86" TOTAL_2="43" VAR="1.2380804953560371" WEIGHT="23.7450868131822"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2013-08-14 08:39:22 +1000" MODIFIED_BY="[Empty name]">
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2013-08-14 08:39:22 +1000" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>'Risk of bias' graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAAEACAMAAABVk4iuAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2013-08-14 08:39:22 +1000" MODIFIED_BY="[Empty name]" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>'Risk of bias' summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAT8AAAInCAIAAABhqcmXAAAZ00lEQVR42u3dsY4cxxWF4QUMGA42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=
</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-02-18 14:01:48 +1000" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2013-05-31 13:07:46 +1000" MODIFIED_BY="[Empty name]">Details of previous searches</TITLE>
<APPENDIX_BODY MODIFIED="2013-08-09 21:29:39 +1000" MODIFIED_BY="[Empty name]">
<P>For the 2011 update we searched the Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library </I>2011, Issue 1), which includes the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (January 2008 to March week 4, 2011) and EMBASE (December 2007 to April 2011).</P>
<P>In the 2007 update we searched the Cochrane Central Register of Controlled Trials (<I>The Cochrane Library </I>2008, Issue 1) which includes the Cochrane Acute Respiratory Infections (ARI) Group's Specialised Register, MEDLINE (1966 to January week 1, 2008), EMBASE (1980 to December 2007) and the National Research Register (Issue 3, 2007).</P>
<P>We searched MEDLINE using the following keywords and MeSH terms in conjunction with the highly sensitive search strategy designed by The Cochrane Collaboration for identifying controlled trials (<LINK REF="REF-Dickersin-1994" TYPE="REFERENCE">Dickersin 1994</LINK>). We used the same strategy to search CENTRAL and adapted it to search EMBASE.</P>
<P>
<B>MEDLINE (OVID)</B>
<BR/>#1. exp MEASLES/<BR/>#2. exp MEASLES VIRUS/<BR/>#3. measles.mp.<BR/>#4. or/1-3<BR/>#5. exp Anti-Bacterial Agents/<BR/>#6. antibiotic$.mp.<BR/>#7. exp QUINOLONES/<BR/>#8. quinolone$.mp.<BR/>#9. exp SULFONAMIDES/<BR/>#10. sulfonamide$.mp.<BR/>#11. exp PENICILLINS<BR/>#12. penicillin$.mp.<BR/>#13. exp MACROLIDES<BR/>#14. macrolide$.mp.<BR/>#15. 0r/5-14<BR/>#16. 4 and 15<BR/>
</P>
<P>
<B>EMBASE (EMBASE.Com)</B>
<BR/>#1. 'measles'/exp AND [embase]/lim   <BR/>#2. 'measles virus'/exp AND [embase]/lim   <BR/>#3. measles:ti,ab AND [embase]/lim <BR/>#4. #1 OR #2 OR #3 <BR/>#5. 'antibiotic agent'/exp AND [embase]/lim<BR/>#6. antibiotic*:ti,ab AND [embase]/lim  <BR/>#7. 'quinolone derivative'/exp AND [embase]/lim<BR/>#8. quinolone*:ti,ab AND [embase]/lim  <BR/>#9. 'sulfonamide'/exp AND [embase]/lim   <BR/>#10. sulfonamide*:ti,ab AND [embase]/lim<BR/>#11. 'penicillin derivative'/exp AND [embase]/lim    <BR/>#12. penicillin*:ti,ab AND [embase]/lim              <BR/>#13. 'macrolide'/exp AND [embase]/lim          <BR/>#14. macrolide*:ti,ab AND [embase]/lim       <BR/>#15. #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14<BR/>#16. #4 AND #15                                                </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2013-05-31 13:07:26 +1000" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2011-04-12 12:58:50 +1000" MODIFIED_BY="[Empty name]">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2011-06-27 00:12:42 +1000" MODIFIED_BY="[Empty name]">
<P>1 exp Measles/<BR/>2 exp Measles virus/<BR/>3 measles*.tw.<BR/>4 or/1-3<BR/>5 exp Anti-Bacterial Agents/<BR/>6 Antibiotic Prophylaxis/<BR/>7 antibiotic*.tw.<BR/>8 exp Quinolones/<BR/>9 quinolone*.tw,nm.<BR/>10 exp Sulfonamides/<BR/>11 sulfonamide*.tw,nm.<BR/>12 exp Penicillins/<BR/>13 penicillin*.tw,nm.<BR/>14 exp Macrolides/<BR/>15 macrolide*.tw,nm.<BR/>16 or/5-15<BR/>17 4 and 16        </P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2013-05-31 13:12:26 +1000" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2011-04-07 11:41:04 +1000" MODIFIED_BY="[Empty name]">Embase.com search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2013-05-31 13:12:26 +1000" MODIFIED_BY="[Empty name]">
<P>#19 #11 AND #18 <BR/>#18 #14 NOT #17 <BR/>#17 #16 NOT #15 <BR/>#16 [animals]/lim <BR/>#15 'human'/exp <BR/>#14 #12 OR #13 <BR/>#13 random*:ab,ti OR placebo*:ab,ti OR crossover*:ab,ti OR 'cross over':ab,ti OR allocat*:ab,ti OR (singl* OR doubl*) NEAR/1 blind* OR trial:ti <BR/>#12 'randomized controlled trial'/exp OR 'single blind procedure'/exp OR 'double blind procedure'/exp OR 'crossover procedure'/exp <BR/>#11 #4 AND #10 <BR/>#10 #5 OR #6 OR #7 OR #8 OR #9 <BR/>#9 quinolone*:ab,ti OR sulfonamide*:ab,ti OR penicillin*:ab,ti OR macrolide*:ab,ti <BR/>#8 'quinolone derivative'/exp OR 'sulfonamide'/exp OR 'penicillin derivative'/exp OR 'macrolide'/exp <BR/>#7 'antibiotic prophylaxis'/de <BR/>#6 antibiotic*:ab,ti <BR/>#5 'antibiotic agent'/exp <BR/>#4 #1 OR #2 OR #3 <BR/>#3 measles:ab,ti OR rubeola:ab,ti OR rubeolla:ab,ti OR morbilli*:ab,ti <BR/>#2 'measles virus'/de <BR/>#1 'measles'/de </P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>